Cross-tissue, single-cell stromal atlas identifies shared pathological fibroblast phenotypes in four chronic inflammatory diseases

Ilya Korsunsky^{1-5,15}, Kevin Wei^{1,15}, Mathilde Pohin^{6,15}, Edy Y. Kim^{7,8,15}, Francesca Barone^{9,15}, Joyce B. Kang¹⁻⁵, Matthias Friedrich⁶, Jason Turner⁹, Saba Nayar^{9,10}, Benjamin A. Fisher^{9,10}, Karim Raza⁹, Jennifer L. Marshall⁹, Adam P. Croft⁹, Lynette M. Sholl¹¹, Marina Vivero¹¹, Ivan O. Rosas¹², Simon J. Bowman^{9,10}, Mark Coles⁶, Andreas P. Frei¹³, Kara Lassen¹³, Andrew Filer^{9,10}, Fiona Powrie^{6,16,*}, Christopher D. Buckley^{9,10,16,*}, Michael B. Brenner^{1,7,16,*}, Soumya Raychaudhuri^{1-5,14,16,17,*}

¹Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

²Center for Data Sciences, Brigham and Women's Hospital, Boston, MA, USA.

³Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.

⁴Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.

⁵Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

⁶Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford OX3 7FY, United Kingdom

⁷Harvard Medical School, Boston, MA 02115, USA

⁸Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA

⁹Rheumatology Research Group, Institute for Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Queen Elizabeth Hospital, Birmingham, B15 2WD, UK.

¹⁰NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

¹¹Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

¹²Department of Medicine Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Dallas, TX, USA.

¹³Roche Pharma Research and Early Development, Immunology, Infectious Diseases and Ophthalmology (I2O) Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland

¹⁴Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.

¹⁵These authors contributed equally

¹⁶These authors jointly supervised this work

¹⁷Lead contact

*Correspondence: soumya@broadinstitute.org; mbrenner@research.bwh.harvard.edu, c.d.buckley@bham.ac.uk, fiona.powrie@kennedy.ox.ac.uk

34 Summary

35 Pro-inflammatory fibroblasts are critical to pathogenesis in rheumatoid arthritis, inflammatory bowel disease,
 36 interstitial lung disease, and Sjögren's syndrome, and represent a novel therapeutic target for chronic
 37 inflammatory disease. However, the heterogeneity of fibroblast phenotypes, exacerbated by the lack of a
 38 common cross-tissue taxonomy, has limited the understanding of which pathways are shared by multiple
 39 diseases. To investigate, we profiled patient-derived fibroblasts from inflamed and non-inflamed synovium,
 40 intestine, lung, and salivary glands with single-cell RNA-sequencing. We integrated all fibroblasts into a multi-
 41 tissue atlas to characterize shared and tissue-specific phenotypes. Two shared clusters, CXCL10⁺CCL19⁺
 42 immune-interacting and SPARC⁺COL3A1⁺ vascular-interacting fibroblasts were expanded in all inflamed
 43 tissues and additionally mapped to dermal analogues in a public atopic dermatitis atlas. We further confirmed
 44 these human pro-inflammatory fibroblasts in animal models of lung, joint, and intestinal inflammation. This work
 45 represents the first cross-tissue, single-cell fibroblast atlas revealing shared pathogenic activation states across
 46 four chronic inflammatory diseases.

47 Introduction

48 Fibroblasts are present in all tissues and adopt specialized phenotypes and activation states to perform both
 49 essential functions in development, wound-healing, and maintenance of tissue architecture, as well as
 50 pathological functions such as tissue inflammation, fibrosis, and cancer responses (Koliaraki et al., 2020).
 51 Recent studies of chronic inflammatory disease have leveraged advances in high-throughput single-cell
 52 genomics, particularly single-cell RNA-sequencing (scRNAseq) to identify molecularly distinct fibroblast
 53 populations associated with pathological inflammation in different anatomical sites (Adams et al., 2020;
 54 Habermann et al., 2020; Huang et al., 2019; Kinchen et al., 2018; Martin et al., 2019; Mizoguchi et al., 2018;
 55 Smillie et al., 2019; Zhang et al., 2019). A study of the large intestine from patients with ulcerative colitis (UC)
 56 identified stromal cells expressing Oncostatin-M receptor (OSMR) enriched in biopsies tracking with failure to
 57 respond to anti-TNF therapy (West et al., 2017). Further studies suggested immunomodulatory roles for OSMR⁺
 58 intestinal fibroblasts through interactions with inflammatory monocytes (Smillie et al., 2019) and neutrophils
 59 (Friedrich et al., 2020). Lung investigations identified that COL3A1⁺ACTA2⁺ myofibroblasts, PLIN2⁺
 60 lipofibroblast-like cells, and FBN1⁺HAS1⁺ fibroblasts are expanded in lung biopsies from patients with idiopathic

pulmonary fibrosis (IPF) (Adams et al., 2020; Habermann et al., 2020). In the salivary gland, chronic destructive inflammation in primary Sjögren's syndrome (pSS) with tertiary lymphoid structures is linked to the expansion of PDPN⁺CD34⁻ fibroblasts (Nayar et al., 2019). In the synovial tissue, FAP α ⁺CD90⁺ fibroblasts are expanded in patients with rheumatoid arthritis (RA) (Wei et al., 2020; Zhang et al., 2019) and drive leukocyte recruitment and activation in an animal model of arthritis (Croft et al., 2019).

In each study, inflammation-associated fibroblasts are characterized by their ability to produce and respond to inflammatory cytokines. These cytokines are often members of conserved families that signal through similar downstream pathways and result in similar effector functions (West, 2019). For instance, the inflammatory cytokines IL-6, Oncostatin M (OSM), leukemia inhibitory factor (LIF), and IL-11 all belong to the gp130 family, whose cognate receptor molecules, including IL-6R, OSMR, LIFR, and IL-11R, contain the Glycoprotein 130 (gp130) subunit. In UC, OSMR⁺ fibroblasts express high levels of the IL-11 encoding gene (Smillie et al., 2019). In RA, a subset of FAP α ⁺CD90⁺ synovial fibroblasts produce high levels of IL-6 (Zhang et al., 2019) through an autocrine loop involving LIF and LIFR (Nguyen et al., 2017; Slowikowski et al., 2019). In a mouse model for human IPF, IL-11 producing fibroblasts drive both fibrosis and chronic pulmonary inflammation (Ng et al., 2020). These examples of gp130-family cytokines associated with pro-inflammatory fibroblasts highlight that while individual factors may be tissue-specific, their downstream effects may be shared across diseases. This pattern underlines an important question with clinical implications: are inflammation-associated fibroblasts tissue-specific or do they represent shared activation states that manifest a common phenotype across different diseases? A drug that targets a shared pathogenic phenotype can potentially be used to treat multiple inflammatory diseases. Identifying such shared fibroblast programs presents a major challenge, as these programs are likely to be transient and reversible activation states that vary over the course of a disease, rather than representing a static, committed cell lineage (Wei et al., 2020).

The identification of shared cell states across tissues with scRNAseq has recently become possible with advances in statistical methods for integrative clustering (Butler et al., 2018; Korsunsky et al., 2019; Tran et al., 2020) and reference mapping (Andreatta et al., 2020; Kang et al., 2020; Lotfollahi et al., 2020). Integrative clustering identifies similar cell states across a range of scRNAseq datasets, even when the datasets come from different donors, species, or tissues. For example, using integrative clustering, Zhang et al., 2020 identified shared macrophage activation states across five tissues, and Butler et al., 2018 identified shared pancreatic

89 islet cells between mouse and human datasets. Reference mapping allows rapid comparison of data from a
90 new study to a well annotated reference, even if the study represents a tissue, disease, or species not present
91 in the reference atlas. For instance, Andreatta et al., 2020 mapped T cell subtypes to a scRNAseq atlas of
92 annotated tumor infiltrating T cells, while Lotfollahi et al., 2020 found disease-related immune states by mapping
93 PBMCs from patients with COVID19 to a healthy reference library of immune cells.

94 In this study, we generated single-cell RNAseq profiles of patient-derived CD45⁻ stromal cells and then
95 characterized fibroblasts across multiple inflammatory diseases involving lung, intestine, salivary gland and
96 synovium. After confirming known fibroblast subtypes in our data, we built a *de novo*, integrated fibroblast atlas
97 and identified five shared phenotypes, two of which are consistently expanded in all four inflammatory diseases.
98 Using reference mapping, we map these to human dermal fibroblasts from inflamed and healthy skin and to
99 fibroblasts from mouse models of lung, synovial, and intestinal inflammation to demonstrate the generalizability
00 of our findings. Our integrated resource represents the first systematic examination of fibroblast subsets and
01 activation states in inflamed tissues. Our identification of two pathogenic fibroblast phenotypes that are shared
02 amongst four inflammatory diseases novel avenues for therapeutic targeting. By making available the necessary
03 computational tools to map new datasets to our annotated fibroblast atlas, we provide a common reference for
04 future studies of fibroblasts in tissues and diseases.

05 Results

06 Single-cell transcriptional profiles of fibroblasts in human lung, salivary gland, synovium, and intestine.

07 We used droplet-based scRNAseq to profile individual fibroblasts from a total of 74 high quality samples in lung,
 08 large intestine, lip salivary glands, and joint synovium, selecting donors with inflammatory diseases and controls
 09 (**Figure 1a**). In synovium, we collected arthroplasties and biopsies from 18 patients with RA and 6 with
 10 osteoarthritis (OA) (**Supplementary Table 1**). In the intestine, we collected large intestinal biopsies from
 11 patients with UC (n=8) and control (n=5) donors (**Supplementary Table 2**). Included in the 8 UC samples were
 12 4 patients for whom we had paired inflamed and adjacent non-inflamed tissue biopsies. For the lung analysis,
 13 we acquired lung tissue samples from 19 patients with ILD and 4 control samples from donor lungs
 14 (**Supplementary Table 3**). To examine salivary glands, we used lip biopsy tissue from 7 patients with primary
 15 Sjögren's Syndrome (pSS) and 6 patients with a non-Sjögren's Sicca syndrome, characterized as non-
 16 autoimmune dryness, as control-comparators (**Supplementary Table 4**). In order to enrich for stromal cells, we
 17 used flow cytometry to sort live, CD45⁻EpCAM⁻ cells from intestine and synovium samples (**Figure 1a**), depleting
 18 CD45⁺ immune and EpCAM⁺ epithelial populations (**Supplementary Figure 1a**). We avoided this strategy in
 19 the salivary gland, in order to optimize cell numbers in small biopsies, and in the lung, in which flow cytometry
 20 compromised fibroblast cell yields. We performed droplet-based scRNAseq (10x Genomics) on all samples,
 21 applied stringent QC to remove low quality libraries and cells (**Supplementary Figure 1b-d**), and combined all
 22 data samples to analyze 221,296 high quality cells. Using clustering analysis (**Methods**), we identified 7 major
 23 cell types (**Figure 1b**) with canonical markers (**Figure 1c**): *CDH5*⁺ endothelial cells, *COL1A1*⁺ fibroblasts,
 24 *EPCAM*⁺ epithelial cells, *GFR3*⁺ glial cells, *JCHAIN*⁺ plasma cells, *MCAM*⁺ perivascular mural cells, and *PTPRC*⁺
 25 leukocytes. Consistent with our flow sorting strategy, non-stromal cells (epithelial, glial, and immune) were more
 26 abundant in the salivary gland and lung (**Supplementary Figure 1e**). Importantly, we identified stromal
 27 (endothelial, mural, and fibroblast) populations in all four tissues, allowing us to carry out a focused analysis of
 28 fibroblasts across tissues.

Figure 1. scRNAseq profiles of intestine, lung, salivary gland, and synovium. (a) Surgical samples were collected from intestine, lung, salivary gland, and synovium, from patients with inflammatory-disease and appropriate controls. After tissue disaggregation, all cells from lung and salivary gland and CD45-EpCAM⁺ cells from synovium and intestine were profiled with scRNAseq and (b) analyzed to identify fibroblasts and other major cell types. (c) Cell type annotation was performed with known markers for each major population.

Fibroblast heterogeneity within tissues.

We next examined the heterogeneity of fibroblast cell states within individual tissues. We performed a separate fine-grained clustering analysis for fibroblasts within each of the four tissues and annotated clusters with previously identified states (**Figure 2a**) by comparing published marker genes (**Supplementary Figure 2a-d**)

with cluster markers in our data (**Supplementary Table 5**). In the intestine, we were able to recapitulate 7 of 8 populations identified in (Smillie et al., 2019): crypt-associated WNT2B⁺Fos^{hi} and WNT2B⁺Fos^{lo}, epithelial-supportive WNT5B⁺-1 and WNT5B⁺-2, stem cell niche supporting RSPO3⁺, inflammatory, and myofibroblasts. We note that our data did not support the 2 subtypes of WNT2B⁺Fos^{lo} fibroblasts identified originally in (Smillie et al., 2019). In the lung, Habermann et al., 2020 described 4 states: HAS1⁺, PLIN2⁺, fibroblasts, and myofibroblasts. However, in their analysis, HAS1⁺ cells were identified in only 1 of 30 donors. When we re-analyzed their data to identify clusters shared by multiple donors, we could not distinguish the HAS1⁺ from PLIN2⁺ population and thus merged these two in our annotation. In the salivary gland, the only single-cell study of fibroblasts to date was performed with multi-channel flow cytometry (Nayar et al., 2019), not scRNAseq. The findings here represent the first set of scRNA-seq data in this context. In our single-cell clusters, we identified the two populations previously described (CD34⁺ and CCL19⁺) and confirmed the expression of key distinguishing cytokines and morphogens that they measured by qPCR (**Supplementary Figure 2b**). In the synovium, we clustered 55,143 fibroblasts into 5 major states described in three scRNAseq studies (Croft et al., 2019; Mizoguchi et al., 2018; Zhang et al., 2019). These states are largely correlated with anatomical position: THY1⁺PRG4⁺ cells in the synovial boundary lining layer and THY1⁺, DKK3⁺, HLA-DRA⁺, and CD34⁺ cells within the sublining. In total, we labeled 17 fibroblast clusters defined across all four individual tissues.

Next, we asked whether fibroblast states defined within one tissue shared similar expression profiles with states defined in other tissues. We performed cluster marker analysis within each tissue, quantifying the overexpression of each gene in each cluster in terms of the log₂ fold change with other clusters. We plotted 4,897 genes that were overexpressed in at least one cluster and labeled the top 3 markers per cluster (**Figure 2b**). We noticed that many marker genes were present in clusters from different tissues. To find which pairs of clusters across tissues were most similar, we correlated (differential) expression profiles (**Methods**) for cross-tissue clusters (**Figure 2c**). The most correlated (Pearson $r = 0.44$, $p = 10^{-29}$) pair of clusters contained CD34⁺ fibroblasts in the salivary gland and CD34⁺ sublining (SC-F1) fibroblasts in the synovium (**Figure 2d**). Although they shared multiple marker genes (*PAMR1*, *MFAP5*, *CD34*, *CD70*, *DPP4*, *FABP3*, and *FNDC1*), they also had tissue-related, cluster-specific genes (*POSTN*, *RAMP1*, *PRG4*, *PI16*, and *TNMD*). The shared markers

66 suggest a shared function. The cluster-specific genes may have arisen from a technical artefact, such
67 as different clustering parameters in the tissue-specific analyses, or from true biological signal, such
68 as a tissue-specific microenvironment. In order to distinguish between the two possibilities, we decided
69 to perform a single integrative clustering analysis with fibroblasts from all tissues.

70 **Figure 2. Fibroblast heterogeneity within tissues.** (a) We analyzed
71 fibroblasts separately from each tissue to
72 identify tissue-specific subsets described
73 in previous single-cell studies. Each panel
74 shows a UMAP representation of
75 fibroblasts from one tissue, labeled with
76 clustering and marker analysis. (b) All
77 (n=7,380) genes nominally upregulated in
78 any cluster were plotted in a heatmap.
79 Color denotes the log fold change,
80 normalized by estimated standard
81 deviation, of a gene in a cluster (versus
82 other clusters in that tissue). Top genes
83 for each cluster were named above the
84 heatmap. Each row denotes a fibroblast
85 cluster, colored by the tissue in which it
86 was identified. (c) To compare the
87 expression profiles of clusters across
88 tissues, we correlated the expression
89 values from (b) for all pairs of clusters.
90 Here, color denotes Pearson's correlation
91 coefficient. (d) One highly correlated pair
92 of clusters from salivary gland (x-axis) and
93 synovium (y-axis) represented by scatter
94 plots of (differential) gene expression.
95 Blue genes are shared by the two
96 clusters, while red genes are unique to
97 one cluster.

98 Integrative clustering of fibroblast across tissues.

00 To construct a cross-tissue taxonomy of fibroblast states, we pooled 55,143 synovial, 15,089 intestinal, 7,474
01 salivary gland, and 1,442 pulmonary fibroblasts together and performed integrative clustering analysis. The
02 different numbers of fibroblasts from each tissue, arising from the fact that we enriched for stromal cells in
03 intestine and synovium but not in lung and salivary gland, presented a technical challenge. The results of many
04 analyses, including PCA, are biased towards tissues with more cells, rather than treating each tissue equally.
05 The second major analytical challenge arises from the fact that gene expression depends on a complex interplay
06 of tissue, donor, and cell state. As we have described in previous work (Korsunsky et al., 2019), such
07 confounding variation is particularly challenging to model in scRNAseq data, as the confounder can have both
08 global and cell-type specific effects on gene expression.

09 We designed an analytical pipeline for integrative clustering to address the two concerns described
10 above (**Figure 3a**). In this pipeline, we select genes that were informative in the tissue-specific analyses
11 (**Methods**), associated with either cluster identity (**Supplementary Table 5**, n=7,123) or inflammatory status
12 (**Supplementary Table 6**, n=6,476) within tissue, for a total of 9,521 unique genes. To minimize the impact of
13 different cell numbers, we performed weighted PCA analysis, giving less weight to cells from over-represented
14 tissues (e.g. synovium) and more to cells from under-represented tissues (e.g. lung), such that the sum of
15 weights from each tissue is equivalent (**Methods**). Compared to unweighted PCA, this approach results in
16 principal components whose variation is more evenly distributed among tissues (**Supplementary Figure 3a**).
17 As expected, in this PCA space, cells group largely by donor and tissue (**Supplementary Figure 3b,c**). In order
18 to appropriately align cell types, we removed the effect of donor and tissue from the cells' PCA embedding
19 coordinates with a novel, weighted implementation of the Harmony algorithm that we developed for this specific
20 application (**Methods**). UMAP visualization of the harmonized embeddings shows that cells from different
21 tissues are well mixed (**Figure 3b**). In contrast, fibroblast states identified in tissue-specific analyses are well
22 separated (**Supplementary Figure 3d**), suggesting that the integrated embedding faithfully preserves cellular
23 composition. In this integrated space, we performed standard graph-based clustering to partition the cells into
24 14 fibroblast states (**Figure 3c**) with representation from all 4 tissues (**Supplementary Figure 3e**). These 14
25 integrated clusters represent putative shared fibroblast states, each of which may be driven by a combination
26 of both shared and tissue-specific gene programs.

Figure 3. Integrative clustering and differential expression across tissues.

(a) We developed a pipeline to integrate samples from multiple donors and multiple tissues with unbalanced cell numbers. The pipeline starts with gene selection, pooling together genes that were informative in single-tissue analyses. With these genes, we performed weighted PCA, reweighting cells to computationally account for the unbalanced dataset sizes among the tissues. These PCs are adjusted with a novel formulation of the Harmony integration algorithm and used to perform graph-based clustering. We applied this pipeline to all fibroblasts across tissues. (b) The integrated UMAP projection shows cells from all tissues mixed in one space. For clarity, we down-sampled each tissue to the smallest tissue, the lung, choosing 1,442 random fibroblasts from intestine, synovium, and salivary gland. (c) Graph-based clustering proposed 14 fibroblast clusters in the integrated embedding. (d) Gene-level analysis to find upregulated marker genes for clusters was done with hierarchical regression, to model complex interactions between clusters and tissues. This strategy distinguishes cluster marker genes that are (e) tissue-specific, such as MYH11 in C13, from those that are (f) shared among tissues, such as ADAM12 in C14. Points denote log fold change (cluster vs other fibroblast) and error bars mark the 95% confidence interval for the fold change estimate. (g) The number of shared genes for each cluster, ranked from most to least, prioritizes clusters with large evidence of shared gene expression (in red) from those with little (in black). Marker genes for the 5 shared clusters plotted in a heatmap. Each block represents the (differential) gene expression of a gene (column) in a cluster, for a tissue (row).

Identification of shared and tissue-specific marker genes in integrated clusters.

Next, we modeled gene expression to define active gene programs in the 14 integrative fibroblast clusters. In particular, we wanted to distinguish between two types of cluster markers: tissue-shared and tissue-specific. Tissue-shared markers are highly expressed in the cluster for all four tissues. Tissue-specific markers are highly expressed in the cluster for at least one tissue but not highly expressed in at least one other tissue. In our expression modeling analysis, we needed to allow for the possibility that tissue gene expression will be consistent in clusters and variable in others (Figure 3d). As we explain in our approach below, we will use

78 ADAM12 expression in cluster C4 as an example of a tissue-shared gene and MYH11 expression in cluster
79 C13 as an example of a tissue-specific gene.

80 Typically, cluster marker analysis is done with regression, to associate gene expression with cluster
81 identity. To address the complex interaction between cluster and tissue identity in our data, we used mixed-
82 effects regression to perform hierarchical cluster marker analysis (**Methods**). This analysis estimated two sets
83 of differential expression statistics for each gene: mean $\log_2$ fold change (e.g. cluster 0 vs all other clusters) and
84 tissue-specific $\log_2$ fold change (e.g. cluster 0 in lung vs all other clusters in lung). This approach distinguishes
85 shared marker genes, defined by minimal tissue-specific contributions, from tissue-specific marker genes,
86 defined by large tissue-specific fold changes, relative to the mean fold change. To demonstrate, we plotted the
87 estimated $\log_2$ fold changes, with a 95% confidence interval, for one shared (**Figure 3e**) and one tissue-specific
88 (**Figure 3f**) cluster marker. ADAM12, a shared marker for cluster C4, has significant ($\log_2$ fold-change = 1.6,
89 $p = 6.5 \times 10^{-9}$) mean differential expression in C4, while the tissue-specific effects (in color) are not significantly
90 different for any one tissue (**Figure 3e**). In contrast, MYH11, is differentially overexpressed in cluster C13 for
91 intestinal ($\log_2$ fold-change = 3.7, $p = 8.5 \times 10^{-16}$) and lung fibroblasts ($\log_2$ fold-change = 2.6, $p = 5.9 \times 10^{-7}$)
92 but not for synovial or salivary gland cells (**Figure 3f**). Because MYH11 is so strongly overexpressed in intestinal
93 and lung fibroblasts, the mean $\log_2$ fold-change is also significant ($\log_2$ fold-change = 1.7, $p = 5.7 \times 10^{-9}$) and
94 therefore is not a good metric alone to determine whether a marker is shared or tissue-specific.

95 We defined tissue-shared cluster markers conservatively by requiring a marker gene to be significantly
96 overexpressed in all four tissues, such as ADAM12 above. With this criterion, we quantified the number of
97 shared marker genes per cluster (**Figure 3g**). Clusters C0, C1, C2, C3, C6, C7, C10, C12, and C13 each had
98 fewer than 20 shared markers. Based on this cutoff, we decided that these clusters had too little evidence of
99 shared marker genes to be reliably called shared clusters. We assigned names for the remaining clusters based
00 on their shared gene markers: SPARC⁺COL3A1⁺ C4, FBLN1⁺ C5, PTGS2⁺SEMA4A⁺ C8, CD34⁺MFAP5⁺ C9,
01 and CXCL10⁺CCL19⁺ C11. We then plotted the $\log_2$ fold change values of all 1,524 shared markers for these
02 clusters in **Figure 3h** and report the results of the full differential expression analysis in **Supplementary Table**
03 **7**.

04 Identification of fibroblast states expanded in inflamed tissue.

05 We next addressed which cross-tissue fibroblast states were expanded in inflamed tissues. In order to perform
 06 this association across tissues, we first needed to define a common measure of tissue inflammation. While
 07 histology is often the gold standard to assess inflammation, histological features are inherently biased to tissue-
 08 specific pathology. Instead, we decided to define inflammation in a tissue-agnostic way, as the relative
 09 abundance of immune cells in each sample. While immune cell abundance alone oversimplifies complex
 10 pathological processes, it is a ubiquitous and quantifiable measure of chronic inflammation. We quantified the
 11 fraction of immune cells based on previously labeled scRNAseq clusters (**Figure 1b**), for salivary gland and
 12 lung samples, and based on the proportion of CD45⁺ cells by flow cytometry (**Supplementary Figure 1a**), for
 13 synovium and intestine (**Figure 4a**). We note that these estimates are quantified with dissociated cells from
 14 cryopreserved tissue (**Methods**) and thus lack granulocytes, such as neutrophils, which constitute an important
 15 part of tissue inflammation. In order to get comparable results across tissues, we standardized the raw tissue-

16 specific immune cell
 17 frequencies to a common
 18 scale from 0 (not inflamed)
 19 to 1 (inflamed) (**Figure 4b**).

20 Importantly, this
 21 transformation (**Methods**)
 22 removes the impact of
 23 distributional differences
 24 among tissues and
 25 preserves the order of
 26 scores within each tissue.

27 **Figure 4. Sample level inflammation scores.** We computed the relative abundance of CD45⁺ immune cells to all cells in
 28 each sample. (b) We standardized these frequencies across tissues into an inflammation score that ranges from 0 to 1
 29 and removes distributional differences. (c) Association analysis results between fibroblast cluster abundance and
 30 standardize inflammation scores. Here, each point represents the log fold change in fibroblast cluster abundance with
 31 increasing inflammation and the line represents that point's 95% confidence interval. Red denotes estimates with one-
 32 tailed FDR<5%. (d) The tissue specific results were summarized using meta-analysis. (e) For CXCL10+CCL19+ (C11) and
 33 SPARC+COL3A1+ (C4) fibroblasts, scatterplots relating to standardized inflammation scores (x-axis) to relative fibroblast
 34 frequency (y-axis).
 35

Using these standardized inflammation scores, we performed a separate association analysis with mixed-effects logistic regression for each tissue. This analysis provided, for each tissue and fibroblast state, the effect of increased inflammation on cluster abundance (**Figure 4c**). Positive log odds ratios denote expansion with inflammation whereas negative ratios denote a diminishing population. Some clusters, such as C2, C3, C7, PTGS2⁺SEMA4A⁺ C8, and C12, were significantly (FDR<5%, red) expanded in only one tissue. Others, such as CXCL10⁺CCL19⁺ C11 and SPARC⁺COL3A1⁺ C4, were significantly expanded in multiple tissues. We confirmed that association with normalized inflammation scores did not change the qualitative results within tissue but did make the results more interpretable across tissues (**Supplementary Figure 4**). We then performed a meta-analysis of these tissue-specific effects (**Methods**) to prioritize clusters expanded consistently across all tissues (**Figure 4d**). This meta-analysis identified two fibroblast states significantly expanded in inflamed samples from all 4 tissues (**Figure 4e**): SPARC⁺COL3A1⁺ (C4) ($OR = 10.4$, 95% $CI[6.6, 16.2]$, $p = 9.4 \times 10^{-25}$), and CXCL10⁺CCL19⁺ (C11) fibroblasts ($\log OR = 32.7$, 95% $CI [11.4, 94.0]$, $p = 9.6 \times 10^{-11}$). The reported odds ratio values denote the odds of a cell being in a cluster (versus not) given that it came from an inflamed sample. Because the effects for these clusters were similar across tissues, pooling in the meta-analysis increased the power to detect these abundance changes.

Distinct immune-interacting and vascular-interacting fibroblast states expanded in tissue inflammation.

The two fibroblast states consistently expanded in inflamed tissue are characterized by distinct gene programs (**Figure 5a**) that reflect putative distinct functions during tissue inflammation. To explore these potential roles, we performed gene set enrichment analysis with 6,369 Gene Ontology (Ashburner et al., 2000) and 50 MSigDB hallmarks pathways (Liberzon et al., 2011) (**Supplementary Table 8, Figure 5b**). Marker genes for CXCL10⁺CCL19⁺ fibroblasts were enriched for pathways involved in direct interaction with immune cells, including lymphocyte chemotaxis (GO:0048247, adjusted $p < 0.005$, includes *CCL19*, *CCL2*, *CCL13*), antigen presentation (GO:0019882, adjusted $p < 0.005$, includes *CD74*, *HLA-DRA*, *HLA-DRB1*), and positive regulation of T cell proliferation (GO:0042102, adjusted $p < 0.005$, includes *TNFSF13B*, *VCAM1*, *CCL5*). CXCL10⁺CCL19⁺ fibroblasts show broad evidence of response to key pro-inflammatory cytokines IFN γ (GO:0034341, adjusted $p=0.005$), IFN α (GO:0035455, adjusted $p=0.02$), TNF α (GO:0034612, adjusted $p < 0.005$), IL-1 (GO:0070555, adjusted $p < 0.005$), and IL-12 (GO:0070671, adjusted $p < 0.005$). While TNF α , IL-1, and IL-12 response are broadly enriched in several fibroblast populations, an interferon response (IFN γ and IFN α) is more specific to

64 CXCL10⁺CCL19⁺ fibroblasts. In contrast to these cytokine-signaling pathways, SPARC⁺COL3A1⁺ fibroblast
65 marker genes were enriched in pathways centered around extracellular matrix binding (GO:0050840, adjusted
66 $p < 0.005$, includes *COL11A1*, *SPARC*, *LRRC15*) and disassembly (GO:0022617, adjusted $p = 0.005$, includes
67 *MMP13*, *MMP11*, *FAP*) and numerous developmental pathways (GO:0035904, GO:0060348, GO:0061448,
68 GO:0007492, adjusted $p < 0.005$, includes *COL3A1*, *COL1A1*, *COL5A1*, *TGFB1*).

69 **Figure 5. Distinct gene expression**
70 **profiles for CXCL10⁺CCL19⁺ and**
71 **SPARC⁺COL3A1⁺ states.** (a)

72 Comparison of differential gene
73 expression between
74 CXCL10⁺CCL19⁺ and
75 SPARC⁺COL3A1⁺ fibroblasts shows
76 that these two inflammation-
77 expanded clusters are characterized
78 by distinct genes. Top 10 markers
79 for each cluster are named. (b) Gene
80 set enrichment analysis with Gene
81 Ontology and MSigDB Hallmark
82 pathways shows distinct functions
83 for the C4 (orange) and C11 (lime)
84 states. These states may be
85 explained by response to distinct
86 sets of signaling molecules:
87 inflammatory cytokines for C4
88 (brown) and tissue modeling
89 morphogens for C11 (tan). Heatmap
90 shows normalized enrichment
91 scores from GSEA, focusing on only
92 positive enrichment for clarity. (c)
93 Ligand receptor analysis of
94 endothelial cell crosstalk with
95 fibroblast populations. Each column
96 is a putative ligand receptor cognate
97 pair, faceted by fibroblast subtype.
98 Y-axis represents the strength of the putative crosstalk, while color denotes direction of interaction: (blue) endothelial ligand
99 to fibroblast receptor or (red) fibroblast ligand to endothelial receptor.

101 Together, this suggests that SPARC⁺COL3A1⁺ fibroblasts may be driven by conserved developmental
102 pathways during tissue remodeling in chronically inflamed diseases. Given the extensive enrichment in
103 developmental pathways in these fibroblasts, we hypothesized that this state could be driven by morphogens
104 within the tissue microenvironment. Indeed, we observed enrichment in key morphogen signaling pathways
105 hedgehog (adjusted $p = 0.005$), TGF β (GO:0007179, adjusted $p < 0.005$), WNT (canonical (GO:0060070,
106 adjusted $p = 0.007$) and non-canonical (GO:0035567, adjusted $p = 0.005$)), BMP (GO:0071772, adjusted $p = 0.01$),
107 and Notch (GO:0007219, adjusted $p < 0.005$). Of these pathways, Notch signaling was the most specific to
108 SPARC⁺COL3A1⁺ fibroblasts (**Figure 5b**), with non-significant (raw $p > 0.20$) enrichment in all other clusters.
109 Since we have previously identified Notch3 signaling as a key driver in differentiation of disease-associated

perivascular fibroblasts in RA synovia (Wei et al., 2020), we predict this cluster may represent a similar endothelium-driven, activated fibroblast state across inflammatory diseases involving other organ tissues. We explored this hypothesis with ligand receptor analysis (**Methods**). We started with manually curated cognate ligand and receptor pairs (Ramilowski et al., 2015) and for each pair, looked for high expression of one gene in endothelial cells within our libraries (**Figure 1b**) and its partner in each fibroblast state. Filtering for only differentially expressed genes, we found a total of 63 putative signaling interactions (**Figure 5c**). Notably, 19 of these interactions were between SPARC⁺COL3A1⁺ fibroblasts and endothelial cells, including Notch activation through the DLL4:NOTCH3 interaction, as described earlier in the synovium (Wei et al., 2020), as well as morphogen TGF β , growth factor PDGF β , angiogenic factors Ephrin- α and Ephrin- β (Rudno-Rudzińska et al., 2017), and angiogenic and mitogenic factors MDK and PTN (Weckbach et al., 2012). This large variety of putative signaling interactions (**Figure 5c**), both from and to endothelial cells, suggests that SPARC+COL3A1+ fibroblasts participate in signaling crosstalk with endothelial cells. Together, these pathway and crosstalk analyses suggest two independent, conserved populations that support tissue inflammation: namely immune cell-interacting CXCL10⁺CCL19⁺ immuno-fibroblasts and endothelium-interacting SPARC⁺COL3A1⁺ vascular associated fibroblasts.

Correspondence between fibroblast clusters defined in integrative analysis and single-tissue analyses.

We determined how the clusters labeled in the single-tissue analyses (**Figure 2a**) mapped to our new shared cross-tissue taxonomy. Since we used the same cells for both within-tissue and cross-tissue analyses, we were able to directly compare the overlap (**Methods**) between these two types of state definitions (**Supplementary Figure 5a**). The immuno-fibroblast cluster C11 overlapped significantly ($FDR < 5\%$) with THY1⁺ sublining ($OR = 3.8, 95\% CI[2.2, 6.7]$) and HLA-DRA^{hi} synovial fibroblasts ($OR = 39.2, 95\% CI[22.2, 69.0]$), with CCL19⁺ fibroblasts in the salivary gland ($OR = 9.1, 95\% CI[6.3, 13.0]$), with RSPO3⁺ ($OR = 16.1, 95\% CI[12.0, 21.7]$) and WNT2B⁺Fos^{hi} ($OR = 2.3, 95\% CI[1.7, 3.1]$) fibroblasts in the intestine, and did not overlap significantly with any one cluster in the lung. Here, odds ratio refers to the probability of a cell being in a cross-tissue cluster (versus not), given that the cell belongs to some within-tissue clusters. The vascular-fibroblast cluster C4 was split between DKK3⁺ and THY1⁺ sublining fibroblasts in the synovium, mapped exclusively to myofibroblasts in the lung, split between inflammatory fibroblasts and myofibroblasts in the intestine, and mapped to CD34⁺ fibroblasts in the salivary gland. Notably, none of these associations was one-to-one. HLA-DRA⁺ synovial

fibroblasts, CCL19⁺ salivary gland fibroblasts, and RSPO3⁺ and WNT2B⁺Fos^{hi} intestinal fibroblasts mapped to multiple clusters that were expanded in one or more tissues: C3 (lung and synovium), C2 (synovium), C12 (intestine), and C8 (salivary gland and synovium). Similarly, the myofibroblasts in the lung and intestine, as well as DKK3⁺ synovial fibroblasts mapped to both C13 and to vascular fibroblasts (C4).

Cluster C13 aligned strikingly with intestinal and pulmonary myofibroblasts. Although C13 contained cells from all tissues, it only expressed canonical myofibroblast genes *MYH11*, *MYL9*, and *ACTA2* in intestinal and pulmonary cells (**Supplementary Figure 5b**). While myofibroblasts are absent in synovium, synovial C13 cells may reflect an activated phenotype involved in tissue repair. This is supported by synovial specific upregulation of bone and cartilage reparative genes *TFF3*, *BMP6*, *HTRA1*, and *HBEGF* (**Supplementary Figure 5c**).

In the synovium and intestine, several clusters have previously been shown to be associated with distinct anatomical locations (Mizoguchi et al., 2018; Smillie et al., 2019; Zhang et al., 2019): PRG4⁺ synovial lining fibroblasts, THY1⁺ sublining synovial fibroblasts, WNT5B⁺ villus-associated fibroblasts, and WNT2B⁺ crypt-associated fibroblasts. Many of the integrated clusters we identified grouped along these anatomically defined lines. Clusters C0, C6, C10, and C12 were most associated with PRG4⁺ lining-associated synovial and WNT5B⁺ villus-associated gut fibroblasts, while clusters C1, C2, C3, and C8, mapped to THY1⁺ sublining-associated synovial and WNT2B⁺ crypt-associated gut fibroblasts. Except for cluster C8, these clusters that were strongly associated with anatomical locations in gut and synovium had fewer numbers of shared marker genes across tissues, potentially reflecting tissue-specific functions dictated by the specific anatomical constraints and physiological functions of the tissue.

FBLN1⁺ C5 and CD34⁺MFAP5⁺ C9 states mapped strongly to RSPO3⁺ intestinal, HAS1⁺PLIN2⁺ pulmonary and CD34⁺THY1⁺ synovial fibroblasts. The remaining cluster C7 did not map well to intestinal or synovial clusters. Subsequent analysis of marker genes within tissues suggested enrichment in doublets: epithelial markers *KRT7* and *ADGRF5* in lung and macrophage markers *C1QB*, *C1QA*, and *SPP1* in the salivary gland. This suggests that despite our best efforts to filter doublets during QC preprocessing, some contaminating doublets were retained. This makes further inference about cluster C7 less reliable.

64 Validation in an alternative tissue: dermal fibroblasts in atopic dermatitis.

65 As a proof of principle, we next explored whether the fibroblast states discovered in the four tissues could
66 generalize to a tissue not explored in this study by examining cells from an independent dataset. We analyzed
67 data from a study (He et al., 2020) of atopic dermatitis (AD), a chronic inflammatory condition of the skin (**Figure**
68 **6a**). The authors performed droplet-based scRNAseq on all cells from cryopreserved skin biopsies of 5 patients
69 with AD (4 samples from skin lesions and 5 samples from skin outside of lesions) and 7 healthy donors. After
70 removing low-quality (**Methods**) cells and 3 samples with fewer than 500 high-quality cells, we clustered 29,625
71 cells from 13 samples to identify the following major cell types (**Supplementary Figure 6a-b**): *MLANA*⁺
72 melanocytes, *KRT15*⁺ epithelial
73 cells, *CD3G*⁺ T cells, *C1QB*⁺ myeloid
74 cells, *PROX1*⁺ lymphatic endothelial
75 cells, *ACKR1*⁺ vascular endothelial
76 cells, *ACTA2*⁺ mural cells, and
77 *COL1A1*⁺ fibroblasts. As before, we
78 used immune cell abundance to
79 quantify a relative inflammation
80 score in each sample (**Figure 6b**).
81 Immune cell abundance correlated
82 with histological classification,
83 highest in samples from skin lesions
84 and lowest in samples from non-
85 diseased controls (**Figure 6b**).

86 **Figure 6. Dermal fibroblast scRNAseq profiles mapped to cross-tissue fibroblast atlas.** (a) To validate our results,
87 we mapped scRNAseq profiles of dermal fibroblasts from lesion biopsies from atopic dermatitis (AD) patients, non-lesional
88 biopsies from AD patients, and control skin biopsies from healthy donors. (b) Based on the relative frequency of immune
89 cells in each biopsy, we computed standardized inflammation scores from 0 to 1. (c) We mapped dermal fibroblasts to our
90 fibroblast atlas and (d) labeled dermal fibroblasts according to their most similar atlas cluster. (e) We confirmed that the
91 gene expression profiles of inferred dermal fibroblast clusters correlated with expression profiles of their reference fibroblast
92 clusters. This is demonstrated for clusters C4 and C11 by plotting the (differential) gene expression in dermal (x-axis) vs
93 reference (y-axis) clusters and calling out the top marker genes identified in the reference clusters. (f) Only
94 CXCL10⁺CCL19⁺ (C11) fibroblast frequency was significantly (FDR<5%) associated with dermal inflammation. (g) Cells
95 from skin with lesions (blue) had considerably less evidence of vasculature, measured by the abundance of perivascular
96 mural cells and vascular endothelial cells. (h) Relative abundance of mural and endothelial cells was most strongly
97 associated with cluster C4. Red denotes one-tailed FDR<5%.

We wanted to compare dermal fibroblasts directly to clusters defined in our fibroblast atlas. To do this, we leveraged a novel algorithm, Symphony (Kang et al., 2020) (**Methods**), designed to quickly and accurately map new scRNAseq profiles into a harmonized atlas to compare them with annotated reference cells. Using Symphony, we mapped dermal fibroblasts into our multi-tissue fibroblast atlas and projected them into the reference UMAP space for visual comparison (**Figure 6c**). For quantitative comparison of fibroblast subtypes, we labeled individual dermal fibroblasts by their most similar reference clusters (**Figure 6d**). Dermal fibroblasts mapped primarily to all clusters except C6, C12, and C13, three clusters which we identified as more tissue-specific (**Figure 3g**). We computed marker genes for these clusters in skin (**Supplementary Table 9**) and compared them to the markers we computed in the cross-tissue analysis. Encouragingly, the gene expression profile of each dermal fibroblast cluster most closely resembled that of its corresponding reference cluster (**Supplementary Figure 6c**). As two examples of this expression concordance, we plotted gene expression of immune (C4) and vascular (C11) fibroblasts inferred in the skin dataset versus those labeled in the reference (**Figure 6e**), highlighting the top 10 marker genes upregulated in each of the fibroblast clusters in the reference (**Figure 6e**).

We associated the abundance of inferred dermal fibroblast clusters with the sample-level inflammation score (**Figure 6f**). CXCL10⁺CCL19⁺ (C11) fibroblasts were the most significantly expanded in inflamed skin samples ($OR = 57, 95\% CI [6.5, 503], p = 2 \times 10^{-4}$), even when performing the association within histological groups $OR > 1000, p = 1.8 \times 10^{-11}$) (**Supplementary Figure 6d**). Interestingly, SPARC⁺COL3A1⁺ fibroblasts, expanded in the original four tissues, were less abundant in inflamed skin. Given the previous association of SPARC⁺COL3A1⁺ fibroblasts with vasculature, we explored the relative degree of vascular cell types in each skin sample. Intriguingly, lesional samples had significantly fewer vascular endothelial (one-tailed t-test $p = 0.004$) and perivascular mural (one-tailed t-test $p = 0.07$) cells (**Figure 6g**), as compared to non-lesional and healthy samples together. The lack of vascular fibroblast expansion in inflamed samples from skin lesions is consistent with this decreased vascularization. In fact, the abundance of vascular fibroblasts is associated nominally with the abundance of vascular endothelial cells ($\log OR = 2.5, p = 0.04$) and strongly with perivascular mural cells ($\log OR = 3.2, p = 1.8 \times 10^{-5}$), when taking into account the histological status (**Figure 6h**).

26 Cross-species mapping identifies shared fibroblast activation states in disease animal models of pulmonary,
 27 synovial, and intestinal inflammation.

28 Next, we tested whether our two shared inflammation associated fibroblast subtypes were identifiable in single-
 29 cell datasets from mouse models of tissue inflammation. By defining which aspects of fibroblast-driven
 30 pathology are reproduced in mouse models, it may be possible to elucidate which pathological processes in
 31 murine models best parallel human fibroblast cell states. We found three single-cell RNAseq data sets that
 32 included both inflamed and non-inflamed samples in matched mouse tissues, which we could use to analyze
 33 both the conservation of cluster markers and the expansion of inflammation-associated immuno-fibroblasts and
 34 vascular fibroblasts (**Figure 7a**): Kinchen et al., 2018 profiled 8,113 cells, CD45⁻ gated to enrich for stroma,
 35 from 3 healthy and 3 mice with Dextran Sulfate Sodium (DSS)-induced colitis. Tsukui et al., 2020 profiled 15,095
 36 cells, Col1a1⁺ gated to enrich for fibroblasts, from 2 healthy and 2 bleomycin-induced lung injury mouse lungs.
 37 Wei et al., 2020 profiled 8,738 total synovial cells from mice with K/BxN serum transfer induced arthritis, half
 38 with active inflammation and half with abated disease by inhibition of Notch3 signaling, by genetic knockout
 39 (Notch3^{-/-}) and blocking antibody

40 (anti-Notch3 mAB). Of note, while
 41 the K/BxN transgenic model
 42 generates autoreactive antibodies
 43 through a lymphocyte-mediated
 44 etiology, mice receiving those
 45 autoreactive antibodies through
 46 serum transfer develop arthritis
 47 through a lymphocyte-
 48 independent etiology (Monach et
 49 al., 2007). Therefore, we did not
 50 expect to see changes in the
 51 frequency of T cell interacting
 52 immuno-fibroblasts with this
 53 model.

54 **Figure 7. Replication in disease models of pulmonary, intestinal, and synovial inflammation.** (a) We collected
55 studies of inflammation in mouse models of human disease: bleomycin induced ILD, DSS-induced colitis, and serum
56 transfer arthritis. (b) Fibroblasts from each study were mapped to the human fibroblast atlas and labeled with their most
57 closely mapped clusters. (c) Frequencies of the human inflammatory states C4 and C11 in each study sample, colored to
58 denote samples from animals with high (red) and low (black) inflammation. (d) Gene set enrichment analysis with modules
59 associated with early, acute, and recovery phases of DSS-induced colitis shows that C4 and C11 gene signatures are
60 activated at distinct stages of inflammation. (e) Time course expression profiles of key C4 and C11 marker genes that
61 overlap with the early (yellow) and acute (orange) phase associated modules. Dotted line denotes timepoint (day 7) at
62 which DSS was removed from mice.

63
64 Within each study, we identified fibroblasts (6,979 intestinal, 10,320 pulmonary, and 5,704 synovial) with
65 clustering and marker analyses (**Supplementary Figure 7a,b**). We then mapped these fibroblasts to our human
66 cross-tissue reference with the Symphony pipeline (**Methods**) and labeled mouse cells with the most similar
67 reference fibroblast subtypes (**Figure 7b**). While most clusters were well-represented across tissues, two
68 appeared more tissue-specific (**Supplementary Figure 7c**). Myofibroblast-enriched C13 was mostly absent in
69 synovium, which is known to lack myofibroblasts. Cluster C12, which mapped well to the intestinal WNT5B⁺ 2
70 cluster in our initial analyses (**Supplementary Figure 5a**), was enriched in intestinal fibroblasts in this mouse
71 analysis. To test the degree to which gene markers are conserved between mouse and human, we performed
72 cluster marker analysis in the mouse fibroblasts (**Supplementary Table 10**) and compared cluster expression
73 profiles between mouse genes and human orthologs (**Supplementary Figure 7d**). Importantly, the most similar
74 gene expression profiles were between corresponding clusters in mouse and human. Moreover, for most
75 clusters, expression profiles were even more similar between matched tissues.

76 We next asked whether the same fibroblast subtypes were expanded in inflamed tissues in human
77 disease and mouse models. Thus, we performed differential abundance analysis within each mouse dataset
78 (**Supplementary Figure 7e**), comparing inflamed cases to matched controls (**Methods**) to determine whether
79 the SPARC⁺COL3A1⁺ and CXCL10⁺CCL19⁺ populations expanded in human tissues were also expanded in
80 mouse models (**Figure 7c**). In bleomycin treated lungs, the most expanded populations were SPARC⁺COL3A1⁺
81 ($OR = 5.2, 95\% CI [4.5, 6.0], p < 10^{-8}$) and CXCL10⁺CCL19⁺ ($OR = 3.8, 95\% CI [2.2, 6.6], p = 2.5 \times 10^{-6}$)
82 fibroblasts. In arthritis models, the Notch signaling enriched (**Figure 5b**) SPARC⁺COL3A1⁺ cluster was greatly
83 diminished with therapeutic Notch3 inhibition ($OR = 3.8, 95\% CI [1.5, 9.4], p = 4.1 \times 10^{-3}$). On the other hand,
84 the frequency of lymphocyte-interacting CXCL10⁺CCL19⁺ fibroblasts was not associated with disease activity
85 in arthritic mice ($OR = 1.2, 95\% CI [0.47, 3.3], p = 0.6$). This result is consistent with the known lymphocyte
86 independence of the serum transfer model etiology (Monach et al., 2007). In DSS-induced colitis,
87 CXCL10⁺CCL19⁺ fibroblasts were significantly expanded ($OR = 6.1, 95\% CI [1.9, 19.3], p = 2.3 \times 10^{-3}$), as

88 reported previously (Kinchen et al., 2018), while SPARC⁺COL3A1⁺ fibroblasts were actually diminished ($OR =$
89 0.5 , $95\% CI[0.4, 0.7]$, $p = 9.2 \times 10^{-7}$) in frequency.

90 Temporal ordering of C4 and C11 activation in DSS-induced colitis.

91 We were surprised that SPARC⁺COL3A1⁺ fibroblasts were not significantly expanded in a DSS-induced colitis
92 model, despite their significance in the human cohorts. The lack of SPARC⁺COL3A1⁺ signal could mean that
93 DSS-induced colitis utilizes an alternative inflammatory process. However, the difference may also reflect the
94 kinetics of disease. Since DSS-induced inflammation is an acute process, reversible with removal of the
95 chemical irritant, cross-sectional cellular compositions in that model may differ from compositions of chronically
96 inflamed UC intestine. Specifically, if SPARC⁺COL3A1⁺ fibroblasts are responsible for tissue remodeling to
97 enable leukocyte infiltration, then genes associated with SPARC⁺COL3A1⁺ fibroblasts should precede those
98 associated with CXCL10⁺CCL19⁺ fibroblasts. To test this hypothesis, we used recently published time course
99 transcriptional profiles of DSS-induced colitis, which tracks gene expression changes with the induction and
00 resolution of inflammation (Czarzewski et al., 2019). The authors induced intestinal inflammation in female 8-
01 12 week old C57BL/6J mice by putting DSS in their drinking water for 7 days and allowed resolution of
02 inflammation by removing DSS for another 7. Measuring gene expression profiles with RNAseq approximately
03 every 2 days, the authors defined gene modules M5 and M9 associated with early inflammation (2-4 days), M1,
04 M3, and M4 with acute inflammation (6-8 days), and M5 and M6 with resolution (10-14 days). We analyzed the
05 enrichment of these phase-associated modules in our fibroblast marker profiles to associate the expansion of
06 fibroblast subtypes with distinct phases of DSS-induced inflammation and resolution (**Supplementary Table**
07 **11**). Strikingly, CXCL10⁺CCL19⁺ fibroblasts exclusively mapped to the three acute phase modules, M1, M3, and
08 M4, while SPARC⁺COL3A1⁺ fibroblasts mapped to two early phase modules, M5 and M9 and only the M1 acute
09 phase module (**Figure 7d**). Time course profiles of representative genes demonstrate the early and resolution
10 phase activation of SPARC⁺COL3A1⁺-associated genes and acute phase activation of CXCL10⁺CCL19⁺-
11 associated genes (**Figure 7e**). Given our hypothesis that SPARC⁺COL3A1⁺ fibroblasts are involved in vascular
12 remodeling while CXCL10⁺CCL19⁺ fibroblasts interact with infiltrating immune cells, the early upregulation of
13 SPARC⁺COL3A1⁺-association gene suggests that vascular remodeling precedes leukocyte infiltration in the
14 DSS-colitis model.

16 Discussion

17 In this study, we sought to define whether shared fibroblast states exist across four diverse tissues affected by
 18 clinically distinct inflammatory diseases. We postulated that defining shared pathogenic, inflammation-
 19 associated fibroblast states across diseases will help inform the possibility of common therapeutic strategies
 20 targeting fibroblasts across different inflammatory diseases. Comparison of pathogenic fibroblast phenotypes
 21 across diseases that manifest in different tissues is hampered by the lack of an accepted, tissue-independent
 22 taxonomy enjoyed by immune and vascular cells. We thus approached this question by generating novel single-
 23 cell RNAseq profiles of fibroblasts and analyzing the fibroblasts together to identify shared phenotypes across
 24 diseases. Cross-tissue analysis of gene expression is a challenging task, as evidenced by the plethora of
 25 statistical methods introduced to analyze even non-single-cell, multi-tissue data generated by the Genotype-
 26 Tissue Expression (GTEx) project (GTEx Consortium, 2015). By using sophisticated statistical methods for
 27 cross-tissue analysis, we were able to identify fibroblast phenotypes that were shared by all tissues as well as
 28 fibroblast adaptations unique to a subset of tissues.

29 The lack of universal definitions for key concepts such as fibroblast identity and inflammation scoring
 30 that apply equally well to all tissues presented a major challenge to our effort to associate fibroblast phenotypes
 31 with inflammation. In particular, the lack of a universal, pan-fibroblast surface marker prevented us from directly
 32 isolating fibroblasts with flow cytometry. We addressed this problem with negative selection, using specific
 33 markers to filter out non-fibroblast populations, and thus defining fibroblasts based on high-dimensional single-
 34 cell-RNA-seq data as non-epithelial, non-immune, non-endothelial, and non-mural cells with some known
 35 tissue-specific fibroblast markers, such as PDPN, PDGFRA, and COL1A1. The lack of a quantifiable score for
 36 inflammation impeded us from directly using standard tools from meta-analysis, which assume a standardized
 37 phenotype that can be measured equally well across all organ tissues. Inflammation in each disease is defined
 38 by disease-specific pathological processes, reflected in tissue-specific histological scores, such as the Krenn
 39 inflammation score in RA (Krenn et al., 2006) and Nancy index in UC (Marchal-Bressenot et al., 2017). We
 40 approached this challenge by intentionally selecting four chronic inflammatory diseases with distinct
 41 pathological and inflammatory processes. By analyzing fibroblasts from a range of diverse pathologies, we
 42 maximized the chances of identifying fibroblast phenotypes common to inflammation in four tissues. We chose
 43 the simplest aspect of inflammation that can be measured in all tissues, namely the proportion of immune cells

44 infiltrating each tissue sample. Despite this simplicity, our definition robustly identified two shared fibroblast
 45 states, CXCL10+CCL19+ (C11) and SPARC+COL3A1+ (C4), associated with inflammation across tissues. A
 46 caveat of our definition of inflammation is that the other fibroblast clusters may be associated with distinct
 47 aspects of inflammation. For instance, PTGS2+SEM4A+ (C8) fibroblasts express neutrophil recruiting genes
 48 *CXCL1* and *CXCL2*, are critical to inflammation in UC (Friedrich et al., 2020), and likely associated with
 49 neutrophil infiltration.

50 The complexity of our study design, with cells measured from multiple donors, tissues, and diseases,
 51 presented a second major challenge to our study. Algorithms to identify shared clusters in scRNAseq datasets
 52 from multiple donors and tissues do not address key issues such as data imbalance or downstream analysis of
 53 gene expression in multi-tissue studies of human disease. Analyses that don't account for these factors in this
 54 complex setting may result in diminished power and spurious associations. Here we use weighted PCA and
 55 weighted Harmony to account for imbalanced datasets and mixed effects Poisson regression to account for the
 56 effect of complex interactions between covariates on gene expression. Our analytical approach to decipher
 57 tissue-shared and tissue-specific gene expression serves as a template for well-powered and robust analysis
 58 of single-cell cluster markers, particularly relevant with the growing number of studies designed to identify
 59 shared etiology across tissues and diseases (Nieto et al., 2020; Szabo et al., 2019; Zhang et al., 2020).

60 Based on marker gene profiles, we believe that some of the clusters named in our analysis have been
 61 previously described in single-cell and functional studies of individual tissues, potentially with the exception of
 62 pSS, in which a scRNAseq atlas has not been described to date. For the first time, we provide a common frame
 63 of reference to cross-compare these diverse populations objectively across tissues. As a powerful corollary, we
 64 can draw upon functional studies performed in individual tissues to interpret the biological significance of our
 65 clusters.

66 CXCL10+CCL19+ (C11) fibroblasts closely resemble functionally well-characterized CCL19+PDPN+
 67 immunofibroblasts in the salivary gland. These CCL19⁺ fibroblasts co-localize with CD3⁺ T cells and underlie
 68 the formation of salivary gland tertiary lymphoid structures in both human tissue and in an animal model (Nayar
 69 et al., 2019). This putative interaction with T cells is suggested by the expression of HLA genes in the synovial
 70 fibroblasts expanded in RA patients (Zhang et al., 2019). Here, HLA-DRA⁺ fibroblasts show strong evidence of
 71 response to IFN γ and functional work demonstrated that IFN γ is mostly produced by CD8⁺ T cells in inflamed

synovium. Kinchen et al., 2018 also identified CCL19⁺ fibroblasts in the inflamed UC intestine, and numerous studies (Bisping et al., 2001; Breese et al., 1993) have associated T cells as the primary source of IFN γ in intestinal inflammation. This suggests that T cell recruitment driven by CCL19⁺ fibroblasts and IFN-activated fibroblasts is a shared feature of inflammation across multiple diseases. Additional functional studies are required to investigate the complex interactions between T cells and fibroblasts in individual inflammatory diseases. Our integrative results provide generalizable markers that may identify such T cell interacting fibroblasts across tissues.

SPARC⁺COL3A1⁺ (C4) fibroblasts closely resemble the CD90^{hi} NOTCH3-activated synovial fibroblasts that are located near arterial blood vessels and pericytes and expanded in RA (Wei et al., 2020). Despite their perivascular location, NOTCH3⁺ fibroblasts, like our SPARC⁺COL3A1⁺ fibroblasts, are distinct from pericytes, as evidenced by their lack of canonical pericyte genes ACTA2 and MCAM (Armulik et al., 2011). Our cross-tissue analysis suggests that these vascular fibroblasts, which clustered separately from MCAM⁺ pericytes (**Figure 1**), may also play a role in vascular remodeling in the lung, intestine, and salivary gland. In the time-series analysis of acute inflammation in the mouse intestine, we found that the expansion of vascular fibroblasts preceded the expansion of CXCL10⁺CCL19⁺ immune-interacting fibroblasts. If this temporal ordering holds tissues, it suggests a two-stage mechanism for fibroblast-mediated regulation of inflammation, initiated by vascular remodeling that enables greater leukocyte infiltration into the tissue. Further mechanistic studies are needed to elucidate both the additional endothelium-derived, or angiocrine factors (Rafii et al., 2016) that mediate perivascular fibroblast differentiation and the mechanistic relationship between vascular and immune-interacting fibroblasts.

In interpreting clusters with more tissue-specific than tissue-shared genes, we noticed that tissue-specific programs often express genes with tissue repair functions. This observation may reflect the tissue-specific needs for maintenance and repair, defined by that tissue's unique anatomical structures (Chang et al., 2002). In contrast, clusters with more tissue-shared genes were enriched in biological processes, such as immune cell recruitment (C11 and C8), processes which are independent of tissue architecture, and interaction with blood vessels (C4), structures which are present in all tissues. This dichotomy between functions tailored to a tissue's structural composition versus functions common to all tissues explain why some fibroblasts phenotypes in scRNAseq appear more tissue-specific and others more tissue-shared.

We used a novel type of analysis from single-cell analysis called Symphony reference mapping (Kang et al., 2020) to compare human dermal fibroblasts and mouse lung, synovial, and lung fibroblasts to our annotated cross-tissue atlas. Reference mapping let us avoid intensive and error-prone manual interpretation steps in *de novo* analysis of the external datasets. We anticipate that this strategy can improve reproducibility in single-cell analysis in general and particularly in fibroblasts, whose phenotypes are often difficult to identify with one or two canonical marker genes. To promote reproducible research and cross-disease insights in fibroblast biology, we made both the fibroblast atlas (github.com/immunogenomics/fibroblastlas) and the tools needed to map data (github.com/immunogenomics/symphony) publicly available.

Fibroblasts are essential players in inflammatory disease, fibrotic disease, and cancer. The potential to target fibroblasts therapeutically is growing with the number of single-cell and functional studies on fibroblast heterogeneity (Dakin et al., 2018). While early studies of fibroblast heterogeneity focused on positional identity, more recent studies focus on functional states that mediate pathological processes. Our study provides the first cross-tissue analysis that rigorously distinguishes tissue-specific from tissue-shared identity in fibroblasts. In doing so, we described two fibroblast states that may be universal to inflammatory disease across tissues. In the process, we created the first single-cell reference atlas of fibroblast heterogeneity to unify fibroblast research and prevent a babelesque sprawl of fibroblast names across disciplines. Finally, we have proposed an analytical pipeline for studying shared pathological processes across diseases that can readily be applied to all cell types and tissues.

19 Acknowledgements

20 We thank David Lee for having the vision and organizing this Roche network to study stromal biology across
 21 tissues. K.W. is supported by a NIH-NIAMS Clinical Investigator Award (1K08AR077037-01) and a BWH
 22 Department of Medicine Innovation Evergreen Award. B.A.F and S.J.B. have received support from the National
 23 Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and the NIHR/Wellcome Trust
 24 Birmingham Clinical Research Facility. S.R. is supported by funding from the National Institutes of Health
 25 (U19AI111224, U01 HG009379, and R01AI049313). K.R. is supported by the NIHR Birmingham
 26 Biomedical Research Centre.

27

28 Author contributions

29 I.K., K.W., and M.P. conceptualized study and co-wrote manuscript under supervision of S.R., M.B.B.,
 30 C.D.B., and F.P.. I.K. and J.B.K. performed analyses. K.W., M.P., E.Y.K., M.F., J.T., and S.N.
 31 performed experiments. E.Y.K., .A.F., K.R., F.B., B.A.F., S.J.B., C.D.B., and A.P.C. performed sample
 32 acquisition. All authors discussed results and commented on manuscript.

33 Declaration of Interests

34 The authors have no declarations of interest to report.

36 Data Statement

37 All FASTQ files and gene count matrices will be made available on NIAID ImmPort servers upon publication.

38

39 Figure Legends

40 **Figure 1. scRNAseq profiles of intestine, lung, salivary gland, and synovium.** (a) Surgical samples were
41 collected from intestine, lung, salivary gland, and synovium, from patients with inflammatory-disease and
42 appropriate controls. After tissue disaggregation, all cells from lung and salivary gland and CD45-EpCAM- cells
43 from synovium and intestine were profiled with scRNAseq and (b) analyzed to identify fibroblasts and other
44 major cell types. (c) Cell type annotation was performed with known markers for each major population.

45

46 **Figure 2. Fibroblast heterogeneity within tissues.** (a) We analyzed fibroblasts separately from each tissue
47 to identify tissue-specific subsets described in previous single-cell studies. Each panel shows a UMAP
48 representation of fibroblasts from one tissue, labeled with clustering and marker analysis. (b) All (n=7,380)
49 genes nominally upregulated in any cluster were plotted in a heatmap. Color denotes the log fold change,
50 normalized by estimated standard deviation, of a gene in a cluster (versus other clusters in that tissue). Top
51 genes for each cluster were named above the heatmap. Each row denotes a fibroblast cluster, colored by the
52 tissue in which it was identified. (c) To compare the expression profiles of clusters across tissues, we correlated
53 the expression values from (b) for all pairs of clusters. Here, color denotes Pearson's correlation coefficient. (d)
54 One highly correlated pair of clusters from salivary gland (x-axis) and synovium (y-axis) represented by scatter
55 plots of (differential) gene expression. Blue genes are shared by the two clusters, while red genes are unique
56 to one cluster.

57

58 **Figure 3. Integrative clustering and differential expression across tissues.** (a) We developed a pipeline to
59 integrate samples from multiple donors and multiple tissues with unbalanced cell numbers. The pipeline starts
60 with gene selection, pooling together genes that were informative in single-tissue analyses. With these genes,
61 we performed weighted PCA, reweighting cells to computationally account for the unbalanced dataset sizes
62 among the tissues. These PCs are adjusted with a novel formulation of the Harmony integration algorithm and
63 used to perform graph-based clustering. We applied this pipeline to all fibroblasts across tissues. (b) The
64 integrated UMAP projection shows cells from all tissues mixed in one space. For clarity, we down-sampled each
65 tissue to the smallest tissue, the lung, choosing 1,442 random fibroblasts from intestine, synovium, and salivary

gland. (c) Graphed-based clustering proposed 14 fibroblast clusters in the integrated embedding. (d) Gene-level analysis to find upregulated marker genes for clusters was done with hierarchical regression, to model complex interactions between clusters and tissues. This strategy distinguishes cluster marker genes that are (e) tissue-specific, such as MYH11 in C13, from those that are (f) shared among tissues, such as ADAM12 in C14. Points denote log fold change (cluster vs other fibroblast) and error bars mark the 95% confidence interval for the fold change estimate. (g) The number of shared genes for each cluster, ranked from most to least, prioritizes clusters with large evidence of shared gene expression (in red) from those with little (in black). Marker genes for the 5 shared clusters plotted in a heatmap. Each block represents the (differential) gene expression of a gene (column) in a cluster, for a tissue (row).

Figure 4. Sample level inflammation scores. We computed the relative abundance of CD45⁺ immune cells to all cells in each sample. (b) We standardized these frequencies across tissues into an inflammation score that ranges from 0 to 1 and removes distributional differences. (c) Association analysis results between fibroblast cluster abundance and standardize inflammation scores. Here, each point represents the log fold change in fibroblast cluster abundance with increasing inflammation and the line represents that point's 95% confidence interval. Red denotes estimates with one-tailed FDR<5%. (d) The tissue specific results were summarized using meta-analysis. (e) For CXCL10+CCL19⁺ (C11) and SPARC+COL3A1⁺ (C4) fibroblasts, scatterplots relating to standardized inflammation scores (x-axis) to relative fibroblast frequency (y-axis).

Figure 5. Distinct gene expression profiles for CXCL10⁺CCL19⁺ and SPARC⁺COL3A1⁺ states. (a) Comparison of differential gene expression between CXCL10⁺CCL19⁺ and SPARC⁺COL3A1⁺ fibroblasts shows that these two inflammation-expanded clusters are characterized by distinct genes. Top 10 markers for each cluster are named. (b) Gene set enrichment analysis with Gene Ontology and MSigDB Hallmark pathways shows distinct functions for the C4 (orange) and C11 (lime) states. These states may be explained by response to distinct sets of signaling molecules: inflammatory cytokines for C4 (brown) and tissue modeling morphogens for C11 (tan). Heatmap shows normalized enrichment scores from GSEA, focusing on only positive enrichment for clarity. (c) Ligand receptor analysis of endothelial cell crosstalk with fibroblast populations. Each column is a putative ligand receptor cognate pair, faceted by fibroblast subtype. Y-axis represents the strength of the

94 putative crosstalk, while color denotes direction of interaction: (blue) endothelial ligand to fibroblast receptor or
95 (red) fibroblast ligand to endothelial receptor.

96

97 **Figure 6. Dermal fibroblast scRNAseq profiles mapped to cross-tissue fibroblast atlas.** (a) To validate
98 our results, we mapped scRNAseq profiles of dermal fibroblasts from lesion biopsies from atopic dermatitis (AD)
99 patients, non-lesional biopsies from AD patients, and control skin biopsies from healthy donors. (b) Based on
00 the relative frequency of immune cells in each biopsy, we computed standardized inflammation scores from 0
01 to 1. (c) We mapped dermal fibroblasts to our fibroblast atlas and (d) labeled dermal fibroblasts according to
02 their most similar atlas cluster. (e) We confirmed that the gene expression profiles of inferred dermal fibroblast
03 clusters correlated with expression profiles of their reference fibroblast clusters. This is demonstrated for
04 clusters C4 and C11 by plotting the (differential) gene expression in dermal (x-axis) vs reference (y-axis) clusters
05 and calling out the top marker genes identified in the reference clusters. (f) Only CXCL10⁺CCL19⁺ (C11)
06 fibroblast frequency was significantly (FDR<5%) associated with dermal inflammation. (g) Cells from skin with
07 lesions (blue) had considerably less evidence of vasculature, measured by the abundance of perivascular mural
08 cells and vascular endothelial cells. (h) Relative abundance of mural and endothelial cells was most strongly
09 associated with cluster C4. Red denotes one-tailed FDR<5%.

10

11 **Figure 7. Replication in disease models of pulmonary, intestinal, and synovial inflammation.** (a) We
12 collected studies of inflammation in mouse models of human disease: bleomycin induced ILD, DSS-induced
13 colitis, and serum transfer arthritis. (b) Fibroblasts from each study were mapped to the human fibroblast atlas
14 and labeled with their most closely mapped clusters. (c) Frequencies of the human inflammatory states C4 and
15 C11 in each study sample, colored to denote samples from animals with high (red) and low (black) inflammation.
16 (d) Gene set enrichment analysis with modules associated with early, acute, and recovery phases of DSS-
17 induced colitis shows that C4 and C11 gene signatures are activated at distinct stages of inflammation. (e) Time
18 course expression profiles of key C4 and C11 marker genes that overlap with the early (yellow) and acute
19 (orange) phase associated modules. Dotted line denotes timepoint (day 7) at which DSS was removed from
20 mice.

21

22 **Supplementary Figure 1. scRNAseq profiles of intestine, lung, salivary gland, and synovium.** (a) Flow
 23 sorting synovial and intestinal surgical samples to enrich for live (FVD⁻), EpCAM⁺CD45⁻ stromal cells. Cell level
 24 quality control summaries for scRNAseq libraries, represented with density plots of (b) percentage of
 25 mitochondrial reads and (c) the number of unique genes in a cell. (d) percentage of cells that were inferred to
 26 be doublets, of those that passed QC filtering ($\%MT \leq 20$, $nGene \geq 500$). (e) Number of stromal and non-stromal
 27 cells identified in each tissue.

28
 29 **Supplementary Figure 2. Labeling of previously defined fibroblast subtypes in each tissue.** Heatmaps
 30 represent the differential expression (one cluster vs all other clusters) z-scores of markers previously associated
 31 with published fibroblast subtypes in (a) synovium, (b) salivary gland, (c) intestine, and (d) lung. Columns
 32 (genes) colored by the fibroblast subtypes they are associated with.

33
 34 **Supplementary Figure 3. Integrated cross-tissue fibroblast reference atlas.** (a) Breakdown of variance
 35 captured in the first 10 principle components for unweighted PCA and weighted PCA shows that weighted PCA
 36 creates a more balanced embeddings among tissues. (b) Before Harmony integration, UMAP embedding of
 37 fibroblasts separates entirely by tissue. (c) Within each tissue, there is substantial separation by donor, denoted
 38 by a different hue of the corresponding tissue's color. UMAP coordinates are the same as in (b), zoomed in to
 39 focus on each tissue separately. (d) After Harmony integration, the clusters identified in tissue-specific analyses
 40 are still separated, suggesting that the Harmony embedding preserves within tissue variation. (e) Relative
 41 abundance integrative fibroblast clusters within each tissue.

42
 43 **Supplementary Figure 4. Inflammation scores.** Comparison of differential abundance analysis using raw
 44 tissue-specific scores (x-axis) and normalized cross-tissue scores (y-axis). Error bars denote 95% confidence
 45 intervals.

46 **Supplementary Figure 5. Correspondence analysis.** (a) We associated cluster identity derived in single-
 47 tissue analyses (columns) to cluster identity derived in the integrative clustering analysis (rows). Color denotes
 48 (scaled) log odds from logistic regression. (b) Gene expression fold change of genes associated with

49 myofibroblast lineage in cluster C13 (vs other clusters). (c) Same, for genes associated with bone and cartilage
50 repair.
51

52 **Supplementary Figure 6. Dermal fibroblast scRNAseq profiles mapped to cross-tissue fibroblast atlas.**
53 (a) UMAP embedding of scRNAseq profiles of skin biopsies, colored by major cell types, using (b) canonical
54 markers: KRT15+ epithelial cells, COL1A1+ fibroblasts, PROX1+ lymphatic endothelial cells, MLANA+
55 melanocytes, C1QB+ myeloid cells, ACTA2+ mural cells, CD3G+ T cells, and ACKR1+ vascular endothelial
56 cells. (c) Correlation of gene expression profiles of dermal fibroblast clusters (y-axis) against reference clusters
57 in multi-tissue atlas (x-axis). Color denotes Pearson's correlation coefficient. (d) Differential abundance of
58 mapped dermal fibroblast clusters with inflammation score, with 95% confidence intervals. Red denotes
59 FDR<5%.
60

61 **Supplementary Figure 7. Replication in disease models.** (a) UMAP embedding of mouse scRNAseq libraries
62 from CD45⁻ sorted colon samples, unsorted synovial samples, and Col1a1⁺ sorted lung samples, colored by
63 major cell types, identified with (b) canonical markers: Cdh5+ vascular endothelial cells, Col1a1+ fibroblasts,
64 Lyve1+ lymphatic endothelial cells, Mcam+ mural cells, Myh11+ myofibroblasts, Ki67 proliferating cells, and
65 Ptprc+ immune cells. (c) Relative abundance of inferred fibroblast clusters in each mouse dataset. (d)
66 Comparison of mouse cluster gene expression profiles (y-axis) to human reference cluster profiles (x-axis).
67 Heatmap color denotes Pearson's correlation coefficient. Columns and rows are colored first by cluster identity
68 and then by tissue. (e) Differential abundance of mapped mouse fibroblast clusters in case vs control mouse
69 samples, with 95% confidence intervals. Red denotes FDR<5%.
70

71 **Supplementary Table 1.** Clinical characteristic for synovial tissue samples. Columns denote unique sample ID
72 for each sample, clinical diagnosis, sex, age (in years), anatomical joint of surgical sample, and seropositivity
73 status.
74 **Supplementary Table 2.** Clinical characteristic for lung tissue samples. Columns denote unique sample ID for
75 each sample, clinical diagnosis, age (in years), sex, and serology.

76 **Supplementary Table 3.** Clinical characteristic for salivary gland tissue samples. Columns denote unique
77 sample ID for each sample, sex, clinical diagnosis, presence or absence of anti-Ro antibodies, focus score, and
78 free-text histology notes.

79 **Supplementary Table 4.** Clinical characteristic for intestine tissue samples. Columns denote unique sample ID
80 for each sample, corresponding donor ID for repeat samples, histological status, year of birth, sex, Nancy score,
81 and anatomical location of biopsy.

82 **Supplementary Table 5.** Cluster marker statistics for fibroblast cluster in single-tissue analyses.
83 LogFoldChange is the differential expression of the gene (Feature) in the cluster (Cluster) against the mean of
84 the remaining clusters within the tissue. Sigma is the estimated standard deviation around the log fold change
85 statistic. Zscore is the standardized log fold change, divided by Sigma. Pval is the one tailed p value for the
86 corresponding z score.

87 **Supplementary Table 6.** Association of inflammation score with pseudobulk fibroblast profiles. Columns same
88 as in Supplementary Table 4, except for Slope, since inflammation score is a continuous and not a categorical
89 covariate.

90 **Supplementary Table 7.** Cluster marker statistics for fibroblast subtypes defined in integrated analysis.
91 Columns same as in Supplementary Table 4.

92 **Supplementary Table 8.** Gene set enrichment analysis of integrated fibroblast cluster markers. Columns are
93 standard output of fgsea function. Pval is the nominal p value, padj is the adjusted p value, ES is the raw
94 enrichment score, NES is the normalized enrichment score, nMoreExtreme is the number of more extreme
95 observations in permutation tests, size is number of genes in the pathway, leadingEdge is the set of genes that
96 contribute to the enrichment score.

97 **Supplementary Table 9.** Cluster marker statistics for dermal fibroblast subtypes. Columns same as in
98 Supplementary Table 4.

99 **Supplementary Table 10.** Cluster marker statistics for mouse synovium, lung, and intestine fibroblast subtypes.
00 Columns same as in Supplementary Table 4.

01 **Supplementary Table 11.** Gene set enrichment analysis of integrated fibroblast cluster markers. Columns
02 same as in Supplementary Table 8.

03 STAR Methods

04 Human research and sample acquisition

05 Synovial study samples for transcriptomic studies were obtained from Brigham and Women's Hospital, Hospital
06 for Special Surgery, and the University of Birmingham under IRB-approved protocols. Synovial tissue from
07 patients with clinically diagnosed rheumatoid arthritis were obtained from ultrasound-guided joint biopsy
08 (University of Birmingham) or arthroplasty or synovectomy procedures (Brigham and Women's Hospital and
09 Hospital for Special Surgery). For arthroplasty and synovectomy tissue samples, the diagnosis of rheumatoid
10 arthritis was confirmed clinically through clinical chart review. Synovial tissue from patients with osteoarthritis
11 were obtained from arthroplasty procedures. Synovial tissues were cryopreserved on-site in Cryostor CS10,
12 then shipped to BWH under a BWH IRB-approved protocol PROSET for tissue dissociation and single-cell
13 transcriptomic analysis.

14 Intestinal samples were obtained from Ulcerative colitis (UC) or from healthy individuals by endoscopic
15 biopsy. Healthy patients were recruited as a part of the research tissue bank ethics 16/YH/0247 and
16 Inflammatory Bowel Diseases (IBD) patients among the Inflammatory Bowel Cohort 09/H1204/30 by the
17 Translational Gastroenterology Unit Biobank at the John Radcliffe Hospital in Oxford. All patients gave informed
18 consent and collection was approved by NHS National Research Ethics Service. Samples were immediately
19 placed on ice (RPMI1640 medium) and processed within 3 hours.

20 Labial minor salivary gland samples were obtained from patients recruited in the Optimising Assessment
21 in Sjögren's Syndrome (OASIS) cohort (Machowicz et al., 2020) which recruits new patients attending the
22 multidisciplinary Sjögren's clinic at the Queen Elizabeth Hospital Birmingham, UK for assessment. Sjögren's
23 syndrome patients had a physician diagnosis of primary Sjögren's syndrome and fulfilled the 2016 ACR/EULAR
24 classification criteria. Participants with non-Sjögren's sicca syndrome had signs and/or symptoms of dryness
25 but did not have a physician diagnosis of SS or fulfill 2016 classification criteria. Salivary gland biopsy samples
26 were divided in two: one for the scRNAseq study and the second for histological analysis to confirm diagnosis.
27 Histological diagnosis is summarized in **Supplementary Table 3** and reported as presence of focal lymphocytic
28 sialadenitis (FLS, suggestive of Primary Sjögren's Syndrome, PSS) or non-specific chronic sialadenitis (NSCS),
29 in the case of non-Sjögren's sicca syndrome. Focus score (FSC, number of inflammatory foci/4mm² of tissue)

30 is also reported in Table 1. All OASIS participants provided written informed consent and the study was
31 approved by the Wales Research Ethics Committee 7 (WREC 7) formerly Dyfed Powys REC; 13/WA/0392.

32 Lung samples were obtained from patients recruited at the Brigham and Women's Hospital with
33 informed consent under protocols approved by the Mass General Brigham IRB (PROSET). As enumerated in
34 Supplementary Table 2, samples coded Lung1-15 (control donor lung, IPF, Rheumatoid Arthritis [RA]-ILD) were
35 explants from lung transplant surgery. Samples coded Lung 16-23 (unclassifiable (u)ILD, IPF, NSIP) were from
36 Video-assisted thoracoscopic surgical (VATS) lung biopsies for diagnosis of ILD. The patient condition is the
37 diagnosis determined by clinical providers after their inter-disciplinary review of patient history, exam, clinical
38 laboratory testing (e.g., serologies), imaging and histopathology of the explanted or biopsied lung tissue. The
39 presence or absence of anti-CCP antibodies is noted.

40 Cell isolation for single-cell RNA-sequencing.

41 Synovial tissues were cryopreserved on site, thawed and disaggregated into single-cell suspension as
42 previously described (Donlin et al., 2018). Four pairs of intestinal biopsies were pooled, minced and frozen in
43 1mL of CryoStor® CS10 (StemCell Technologies) at -80°C then transferred in LN2 within 24 hours. Single-cell
44 suspensions from these endoscopic biopsies were then prepared by thawing, washing and subsequent mincing
45 of the tissue using surgical scissors. Minced tissue was then subjected to rounds of digestion in RPM-1640
46 medium (Sigma) containing 5% Fetal Bovine Serum (FBS, Life Technologies), 5mM HEPES (Sigma), antibiotics
47 as above, and Liberase TL (Sigma), with DNase I. After 30 minutes, digestion supernatant was taken off, filtered
48 through a cell strainer, spun down, and resuspended in 10ml of PBS containing 5% BSA and 5mM EDTA.
49 Remaining tissue was then topped up with fresh digestion medium until no more cells were liberated from the
50 tissue. Cells were then stained and FACS-sorted for live EPCAM⁺CD45⁻ cells, before being taken for microfluidic
51 partitioning.

52 Lung tissues were cryopreserved on site, thawed and disaggregated into single-cell suspension. Each
53 lung tissue was frozen in 1mL of CryoStor CS10 in -80°C with a controlled rate of freezing and then transferred
54 to LN2 within two weeks. On the day of single-cell analysis, the cryopreserved lung tissue was rapidly thawed,
55 serially rinsed with DMEM (GIBCO) supplemented with 10% FBS and then DMEM with 2% FBS on ice. Lung
56 tissue was minced using surgical scissors and then transferred to a polypropylene tube with digestion media
57 containing Liberase TL, hyaluronidase (Worthington Biochemical Corporation), Elastase (Worthington

Biochemical Corporation), DNase (Sigma) and 1% FBS. The addition of FBS improved cell viability without reducing yield of viable stromal cells. After 20 minutes of incubation at 37°C warm room with agitation by stir bar, the supernatant containing single cells was collected, and fresh digestion media was added. After 20 minutes of addition digestion, the tissue and supernatant were filtered through a 70 micron cell strainer and washed in DMEM with 2% FBS twice. Dead cells were removed using a magnetic column based method per manufacturers protocols (Dead Cell Removal kit, Miltenyi Biotec). Then single cells were taken for microfluidic partitioning.

Minor salivary gland biopsies were taken surgically from the lip and frozen in 1mL of CryoStor® CS10 (StemCell Technologies) at -80°C. For preparation of single-cell suspension, firstly the frozen tissue sample in Cryotube were quickly thawed in water bath at 37°C and washed twice in pre-warmed 5%FBS RPMI media. The salivary gland biopsies were then enzymatically digested as previously described (PMID: 31213547). Dead cells were removed using the EasySep™ Dead Cell Removal (Annexin V) kit from the digested samples following manufacturer's instructions before proceeding for the scRNA sequencing using the 10x platform.

RNA-sequencing.

Single-cell RNA-sequencing experiments for lung, intestine, and synovium samples were performed through the Brigham and Women's Hospital Single Cell Genomics Core. Viable cells in single-cell suspension were resuspended in 0.4% BSA in PBS at a concentration of 1,000 cells per ul. 7,000 cells were loaded onto a single lane (Chromium chip, 10X Genomics) followed by encapsulation in lipid droplet, with the 10x Genomics Single-Cell 3' kit (Version 2 for synovium and intestine, Version 3 for lung) followed by cDNA and library generation per manufacturer protocol. cDNA libraries were sequenced to an average of 50,000 reads per cell using Illumina Nextseq 500. Single-cell RNA-sequencing experiments for salivary gland samples were performed at Oxford University. For each library, 10,000 cells were counted using the automated cell counter Bio-Rad TC20 and loaded onto a single 10x lane and processed with the 10x Genomics Single Cell 3' kit (Version 3). Sequencing was done using Illumina NovaSeq 6000 and libraries were sequenced to a minimum of 50000 reads/cell.

scRNAseq gene quantification.

For all scRNAseq datasets analyzed in this manuscript, we quantified gene expression *ab initio* from FASTQ files. Human reads were mapped to the GRCh38 (Schneider et al., 2017) reference and genes annotated with Gencode (Frankish et al., 2019) v33. Mouse reads were mapped to mm10 reference and genes annotated with

86 Gencode v25. For both human and mouse data, we filtered transcripts for the annotation “protein_coding” and
 87 ignored the rest. Reads from distinct transcripts of the same gene were collapsed by summation. We used
 88 kallisto (Bray et al., 2016) v0.46.0 to map reads to transcriptomes and bustools (Melsted et al., 2019) v0.39.3
 89 to collapse duplicate reads by UMI and return gene-cell count matrices. We downloaded read level data for the
 90 following publicly available scRNAseq datasets: PRJNA614539 (He et al., 2020) (atopic dermatitis),
 91 PRJNA542350 (Kinchen et al., 2018) (DSS model), and PRJNA548947 (Tsukui et al., 2020) (Bleomycin model).
 92 After contacting the authors, the PRJNA542350 data turned out to be BAM files rather than FASTQ. Per their
 93 suggestion, we used the 10X Cell Ranger (Zheng et al., 2017) bamtofastq utility (version 1.3.2), with default
 94 parameters, to convert the BAMs back into FASTQs for remapping. doc. The code to perform all steps of this
 95 mapping are implemented as functions in the github repository for this manuscript.

96 [scRNAseq quality control, pre-processing, and normalization.](#)

97 After quantifying gene count matrices with kallisto and bustools (above), we filtered out poor quality cells with
 98 three metrics. (1) Cells must have at least 500 unique genes. (2) Cells must have more than 20% of the total
 99 UMIs mapped to non-mitochondrial genes. (3) Cells must be inferred as singlets by algorithmic doublet
 00 identification. For doublet identification, we used the scDbIFinder algorithm(Germain, 2020), with default
 01 parameters, separately within each 10X library. We normalized for read depth with the standard logCP10K
 02 normalization procedure for gene g and cell i : $Y_{gi} = \log\left(1 + 10^4 \times \frac{U_{gi}}{\sum_h U_{hi}}\right)$.

03 [Inflammation score normalization across tissues.](#)

04 Inflammation scores computed within each tissue had ranges and distributions. To be able to compare
 05 inflammation associated phenotypes across tissues, we normalized the distributions by performing quantile
 06 normalization. Because the number of samples was relatively small, we did not use an empirical distribution.
 07 Instead, we normalized to the quantiles of a parametric distribution. We chose the beta distribution ($\alpha = 3, \beta =$
 08 3) to map the scores to an interpretable interval, between 0 (low inflammation) and 1 (high inflammation).

09 [Gene selection](#)

10 For analyses with one tissue, we used the VST method for variable gene selection, reimplemented from the
 11 Seurat package (Butler et al., 2018) as a stand along function in our github at
 12 immunogenomics/singlecellmethods. We used default parameters and kept the top 2000 genes, ranked by
 13 standardized variance. For the multi-tissue integrated analysis, we used genes that we found informative in at

14 least one of the tissue-specific analyses of lung, salivary gland, intestine, and synovium. We defined informative
15 genes with two analyses. The first analysis is differential expression of cluster-markers for tissue-specific
16 fibroblast subtypes (**Figure 4a**). We kept cluster-informative genes with $p < 0.05$ and $|\beta| \geq 0.5$. The second
17 analysis found broadly inflammation associated genes by fitting a Poisson log-normal GLMMs to each gene.
18 We kept inflammation associated genes with $p < 0.05$ and $|\beta| \geq 0.1$.

19 **Weighted PCA.**

20 We implemented principle components analysis that gives equal weight to each tissue while preserving the total
21 cell number ($\sum_i w_i = N$). The weights given to each cell were determined to meet this equal weight condition.
22 These weights were then used in the scaling and SVD steps. For scaling, we computed weighted means and
23 variance with the following formulas: $\mu_g = \frac{\sum_i w_i y_{gi}}{N-1}$, $\sigma_g^2 = \frac{\sum_i w_i (y_{gi} - \mu_g)^2}{N-1}$. For SVD, we modified the PCA
24 covariance decomposition formula to allow for observation weights with a diagonal matrix W : $XWX^T = UDU^T$.
25 This decomposition is achieved by performing SVD on the weighted matrix $XW^{1/2} = UDV^T$. Because W is
26 diagonal, its square root is the element-wise square root. This SVD solution now represents the original data
27 as $X = UDV^TW^{-1/2}$, with gene loadings U and cell embeddings $V^TW^{-1/2}$. Weighted PCA is implemented on
28 our github at immunogenomics/singlecellmethods with the `weighted_pca` function.

29 **Weighted Harmony.**

30 We modified the Harmony algorithm to include observation weights. To achieve this, we modified the clustering
31 objective function and rederiving the optimization steps for this function. The new objective function modifies
32 the original only by multiply the per-cell cost (inside the summation) by w_i : $\min_{R,Y} \sum_{i,k} w_i [R_{ki} 2(1 - Y_k^T Z_i) +$
33 $\sigma R_{ki} \log R_{ki}] + w_i \left[\sigma \theta R_{ki} \log \left(\frac{O_{ki}}{E_{ki}} \right) \phi_i \right]$. The rest of the formula is unchanged and described in detail in the
34 original Harmony manuscript (Korsunsky et al., 2019). This modified Harmony implementation is available on
35 our github at immunogenomics/harmony, under the weights branch.

36 **UMAP visualization.**

37 We used the UMAP algorithm to visualize cells in two dimensional embeddings. We used the uwot R package
38 (Melville, 2020) with parameters `n_neighbors=30L`, `metric='Euclidean'`, `init='Laplacian'`, `spread=0.3`,
39 `min_dist=0.05`, `set_op_mix_ratio=1.0`, `local_connectivity=1L`, `repulsion_strength=1`, and
40 `negative_sample_rate=1`. For all other parameters, we used default values. In the symphony pipeline, we

visualized mapped query cells by using the UMAP object learned for the reference analysis. The umap reference projection was done with the `umap_transform` function in `uwot`.

43

44 Clustering.

We performed graph based clustering with the Louvain algorithm (Blondel et al., 2008), implemented in Seurat (Butler et al., 2018). Instead of constructing the kNN and sNN graphs from scratch, we used the uniform manifold graph estimated in the UMAP algorithm. In the `uwot` package (Melville, 2020), this data structure is directly available in the `fgraph` field when `umap` is run with option `ret_extra = c('fgraph')`.

49 Hierarchical gene expression modeling.

Statistical model. We modeled the expression of each gene using Poisson lognormal GLMM regression. This framework allows us to model the hierarchical design in our multi-tissue, multi-donor dataset. We fit the following GLMM for the integrated, multi-tissue analysis, regressing to the frequency of gene g in observation i .

$$\log \mu_{gi} \sim \beta_0 + \beta_{cluster} + \beta_{Donor} + \beta_{Donor:Cluster} + \beta_{Tissue} + \beta_{Tissue:Cluster} + offset(\log \sum_h U_{hi})$$

We chose to model the cluster interaction terms with donor and tissue. As many papers have observed (Haghverdi et al., 2018; Korsunsky et al., 2019), the effect of biological and technical covariates are often cell type specific. This is why integration algorithms cannot adjust every cell type by the same amount to account for batch, donor, or tissue variability. Unfortunately, the absence of some donors and tissues in some clusters means that interaction terms may be very poorly estimated. To address this issue, we model all terms except for the global intercept (β_0) with Gaussian priors, allowing each effect to have a different size, denoted by τ^2 , the variance of the priors. These priors shrink β s towards zero, stabilizing estimation for terms with little data to draw from.

We performed cluster marker analysis with the estimated β s, estimating both marginal effects and tissue-specific effects. *Marginal cluster effects* are only concerned with the $\beta_{cluster}$ term. For instance, the differential expression for cluster 3 is $\beta_{C=3} - \frac{1}{n-1} \times (\beta_{C=1} + \beta_{C=2} + \beta_{C=4} + \dots + \beta_{C=n})$. This comparison can be compactly represented with the contrast vector $\Delta = [-\frac{1}{n-1}, -\frac{1}{n-1}, 1, -\frac{1}{n-1}, \dots, -\frac{1}{n-1}]$ such that the differential expression can be computed with the linear operation $\beta_{C=3}^{DGE} = \Delta \beta_{cluster}$. Following the example of significance testing in DESeq2, the standard errors of contrasts are in the diagonal elements of $\sqrt{\Delta \Sigma \Delta^T}$, in which Σ is the

covariance matrix of β levels. In our example, Σ is a cluster by cluster covariance matrix and the standard error for cluster 3 would be $\sigma_{C=3}^{DGE} = \sqrt{\Delta \Sigma_{cluster} \Delta^T_{3,3}}$. There is generally no analytical way to compute Σ for random effects, so we estimate it with simulation, using the arm R package (Gelman and Su, 2020), with 1000 simulations. *Tissue-specific cluster effects* take into account both the cluster and tissue-cluster interaction term. For instance, if we wanted to know how a gene is associated with cluster 3 in the lung, we would compute

$$\beta_{C=3,T=Lung}^{DGE} = \beta_{C=3} - \frac{1}{n-1} \times (\beta_{C=1} + \beta_{C=2} + \beta_{C=4} + \dots + \beta_{C=n}) + \beta_{C=3,T=Lung} - \frac{1}{n-1} \times (\beta_{C=1,T=Lung} + \beta_{C=2,T=Lung} + \beta_{C=4,T=Lung} + \dots + \beta_{C=n,T=Lung}).$$

The contrast vector now includes terms that represent the β s estimated for lung tissue as well. The statistical procedures to compute $\beta_{C=3,T=Lung}^{DGE}$ and $\sigma_{C=3,T=Lung}^{DGE}$ are the same as before. For both marginal and tissue-specific effects, we use a Gaussian approximation to estimate p values for each effect: $\beta^{DGE} \sim N(\Delta \beta, \Delta \Sigma_{cluster} \Delta^T)$.

Implementation. We fit GLMMs with the glmer function in the lme4 R package (Bates et al., 2015) and estimated random effect covariance with the sim function in the R arm package (Gelman and Su, 2020). Initially, we found it difficult to tie model fitting and simulation seamlessly with differential expression analysis. For instance, building contrasts for nested effects and estimating significance for multiple gene queries was difficult to do. Moreover, the memory footprint of lme4 models makes it impractical to fit and save models for 1000s of genes for downstream inference. To make lme4 and arm more accessible for gene expression analysis, we created the Presto package. Presto extracts the necessary components from lme4 models, saves them in efficient data structures, and has all necessary functions to do efficient contrast analysis for differential expression. We made Presto available as an R package, available on github at immunogenomics/presto under the GLMM branch.

To make the models more numerically stable, we enforced a minimum value for the size of random effects: $\sigma \geq 0.5$. This prevented degenerate solutions with $\sigma = 0$, local minima which may arise in GLMM optimization. As a side effect, this Bayesian variance prior also enforces a conservative null model on random effects, effectively setting the null effect size to 0.5 rather than 0. This results in higher estimated uncertainty thus more conservative p values. In developing this software, QQ plot analysis was deflated and resembled post-hoc adjusted (e.g. Bonferroni) p values more than nominal p values from independent tests. Others have noted a similarity between *post hoc* correction and shrinkage integrated into the model (Gelman et al., 2012).

95 For our analyses, we consider significance with respect to these shrunken p values, estimated with random
96 effects, without doing additional *post hoc* shrinkage.

97 We made two decisions to make Presto scale to large datasets. First, we fit the model with pseudobulk,
98 rather than single-cell RNAseq profiles. Note that in the formula above, the cluster, tissue, and donor covariates
99 are not unique to single cells. Therefore, we collapse reads from cells with same cluster, donor, and tissue
00 identity into one observation. This approach has strong precedent(Lun and Marioni, 2017). It is important to
01 note that in this strategy, the number of parameters to estimate is equal to the number of observations. With
02 fixed effects, this model is under-determined. However, because we shrink estimates to 0 with Gaussian priors,
03 the effective number of independent parameters shrinks too. The second decision is with the choice of
04 generative model. Many RNAseq differential expression tools used the Negative Binomial distribution, which
05 uses Gamma rather than lognormal priors to model over-dispersion. For completeness, we also included
06 negative binomial GLMMs in Presto. In practice, we found that this error model yielded almost identical results
07 but took ten times longer to run.

08 **Tissue heterogeneity.** We took a very simple approach to labeling genes as conserved or heterogeneous
09 cluster makers. Conserved markers were significantly ($p < 0.05$) overexpressed ($\beta > 0$) in all four tissues. If a
10 gene was not upregulated in at least one tissue, we considered it to be a heterogeneous marker. Effect
11 heterogeneity has a rich statistical treatment, especially in meta-analysis. We decided to not use these more
12 sophisticated techniques, although the parameters learned in Presto could be used for such analyses.

13 **Analyses.** To find marker genes for dermal fibroblasts, we fit the same model as above but omitted the Tissue
14 terms: $\log \mu_{gi} \sim \beta_0 + \beta_{Cluster} + \beta_{Donor} + \beta_{Donor:Cluster} + offset(\log \sum_h U_{hi})$. For the mouse scRNAseq analyses,
15 we used the same hierarchical formula with all Tissue terms.

16 **Pathway analysis.**

17 All formal geneset enrichment was done with the GSEA algorithm, implemented in the fgsea R
18 package(Sergushichev, 2016). To enrich pathways for marker analyses (**Figure 5d**), we used the H (hallmarks)
19 and C5 (Gene Ontology) genesets from MSigDB, accessed with the msigdb R package(Dolgalev, 2018). To
20 enrich for different phases of inflammatory response in DSS-induced colitis (**Figure 7e**), we used the published
21 genesets, provided as supplemental materials in the manuscript (Czarnewski et al., 2019).

22 Abundance modeling

23 We associated inflammation score with cluster abundance using logistic regression, following the MASC method
 24 (Fonseka et al., 2018), with the following formula: $\log \frac{\Pr(Cluster=k)}{\Pr(Cluster \neq k)} \sim 1 + Score + (1|Library) + (MT +$
 25 $DS|LibraryID)$. As in MASC, the response variable models the log odds of being in cluster k vs not, to test for
 26 which factors contribute to cluster k abundance. This probability is a function of (1) an intercept, which reflects
 27 the average abundance of cluster k in the data, (2) fixed effect for $Score$, the normalized inflammation score for
 28 each sample, (3) random effect for 10X library, to account for dependence of cells within a library, and (4) cell
 29 quality statistics MT (percent mitochondrial reads) and DS (doublet score), separately within each library. The
 30 association between inflammation and cluster abundance is captured in the β statistic. We computed
 31 significance for each β with the following Gaussian approximation, using the standard error σ provided by lme4:
 32 $\beta \sim N(0, \sigma^2)$. To combine MASC results from individual tissue analyses, we used inverse variance weighted meta
 33 analysis with random effects. The variance from random effects was estimated with the DerSimonian and Laird
 34 (DL) method (DerSimonian and Laird, 1986; Veroniki et al., 2016).

35 Cluster correspondence analysis.

36 To compare the co-occurrence of the fibroblast cluster labels, within-tissue (**Figure 3**) and integrative (**Figure**
 37 **4**), we used a similar framework to abundance modeling above. We used the following formula:
 38 $\log \frac{\Pr(Cluster^{Integrated}=k)}{\Pr(Cluster^{Integrated} \neq k)} \sim 1 + (1|Cluster^{Tissue}) + (1|Library) + (MT + DS|LibraryID)$. The contrast term of
 39 interest is the random effect $(1|Cluster^{Tissue})$, a categorical variables that encodes the within-tissue cluster
 40 identity. We chose to model this with a random effect for numerical stability. To estimate significance, we used
 41 Wald's approximation and simulated covariance for the levels of $(1|Cluster^{Tissue})$ with the R arm package.

42 Symphony projection.

43 The Symphony pipeline is described in detail in a separate manuscript (Kang et al., 2020). In order to infer
 44 reference cluster identity in query cells, we used a k-NN classifier. K=10 nearest neighbors were estimated with
 45 Symphony projected low dimensional embeddings, based on cosine distance ($\sigma = 0.1$).

46 Ligand receptor analysis.

47 We started with a curated list of known interacting ligand-receptor pairs, from Ramilowski et al., 2015. To predict
 48 putative interactions between endothelial cells and fibroblast subsets, we performed differential expression on

49 the pooled dataset of endothelial cells and fibroblasts. We filtered for differentially expressed genes and kept
50 interaction pairs in which the ligand was overexpressed ($p < 0.05, \beta > 0$) in endothelial cells and the receptor
51 in a fibroblast subset, or vice versa. For these pairs, we computed the interaction scores (**Figure 4e**) as the
52 mean of the ligand's and receptor's z-scores.

53

54 References

- 55 Adams, T.S., Schupp, J.C., Poli, S., Ayaub, E.A., Neumark, N., Ahangari, F., Chu, S.G., Raby, B.A., Deluliis,
56 G., Januszyk, M., et al. (2020). Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell
57 populations in idiopathic pulmonary fibrosis. *Science Advances* 6, eaba1983.
- 58 Andreatta, M., Corria-Osorio, J., Müller, S., Cubas, R., Coukos, G., and Carmona, S.J. (2020). Projecting
59 single-cell transcriptomics data onto a reference T cell atlas to interpret immune responses.
- 60 Armulik, A., Genové, G., and Betsholtz, C. (2011). Pericytes: developmental, physiological, and pathological
61 perspectives, problems, and promises. *Dev. Cell* 21, 193–215.
- 62 Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M., Davis, A.P., Dolinski, K., Dwight,
63 S.S., Eppig, J.T., et al. (2000). Gene ontology: tool for the unification of biology. The Gene Ontology
64 Consortium. *Nat. Genet.* 25, 25–29.
- 65 Bates, D., Mächler, M., Bolker, B., and Walker, S. (2015). Fitting Linear Mixed-Effects Models Using lme4.
66 *Journal of Statistical Software* 67, 1–48.
- 67 Bisping, G., Lügering, N., Lütke-Brintrup, S., Pauels, H.G., Schürmann, G., Domschke, W., and Kucharzik, T.
68 (2001). Patients with inflammatory bowel disease (IBD) reveal increased induction capacity of intracellular
69 interferon-gamma (IFN-gamma) in peripheral CD8+ lymphocytes co-cultured with intestinal epithelial cells.
70 *Clin. Exp. Immunol.* 123, 15–22.
- 71 Blondel, V.D., Guillaume, J.-L., Lambiotte, R., and Lefebvre, E. (2008). Fast Unfolding of Communities in
72 Large Networks. *J. Stat. Mech: Theory Exp.* 2008.
- 73 Bray, N.L., Pimentel, H., Melsted, P., and Pachter, L. (2016). Near-optimal probabilistic RNA-seq
74 quantification. *Nat. Biotechnol.* 34, 525–527.
- 75 Breese, E., Braegger, C.P., Corrigan, C.J., Walker-Smith, J.A., and MacDonald, T.T. (1993). Interleukin-2-
76 and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. *Immunology* 78,
77 127–131.
- 78 Butler, A., Hoffman, P., Smibert, P., Papalexi, E., and Satija, R. (2018). Integrating single-cell transcriptomic
79 data across different conditions, technologies, and species. *Nat. Biotechnol.* 36, 411–420.
- 80 Chang, H.Y., Chi, J.-T., Dudoit, S., Bondre, C., van de Rijn, M., Botstein, D., and Brown, P.O. (2002).
81 Diversity, topographic differentiation, and positional memory in human fibroblasts. *Proc. Natl. Acad. Sci. U. S.*
82 *A.* 99, 12877–12882.
- 83 Croft, A.P., Campos, J., Jansen, K., Turner, J.D., Marshall, J., Attar, M., Savary, L., Wehmeyer, C., Naylor,
84 A.J., Kemble, S., et al. (2019). Distinct fibroblast subsets drive inflammation and damage in arthritis. *Nature*
85 570, 246–251.
- 86 Czarnewski, P., Parigi, S.M., Sorini, C., Diaz, O.E., Das, S., Gagliani, N., and Villablanca, E.J. (2019).
87 Conserved transcriptomic profile between mouse and human colitis allows unsupervised patient stratification.
88 *Nat. Commun.* 10, 2892.
- 89 Dakin, S.G., Coles, M., Sherlock, J.P., Powrie, F., Carr, A.J., and Buckley, C.D. (2018). Pathogenic stromal
90 cells as therapeutic targets in joint inflammation. *Nat. Rev. Rheumatol.* 14, 714–726.
- 91 DerSimonian, R., and Laird, N. (1986). Meta-analysis in clinical trials. *Control. Clin. Trials* 7, 177–188.
- 92 Dolgalev, I. (2018). msigdb: MSigDB gene sets for multiple organisms in a tidy data format.

- 93 Donlin, L.T., Rao, D.A., Wei, K., Slowikowski, K., McGeachy, M.J., Turner, J.D., Meednu, N., Mizoguchi, F.,
94 Gutierrez-Arcelus, M., Lieb, D.J., et al. (2018). Methods for high-dimensional analysis of cells dissociated from
95 cryopreserved synovial tissue. *Arthritis Res. Ther.* 20, 139.
- 96 Fonseka, C.Y., Rao, D.A., Teslovich, N.C., Korsunsky, I., Hannes, S.K., Slowikowski, K., Gurish, M.F., Donlin,
97 L.T., Lederer, J.A., Weinblatt, M.E., et al. (2018). Mixed-effects association of single cells identifies an
98 expanded effector CD4+ T cell subset in rheumatoid arthritis. *Sci. Transl. Med.* 10.
- 99 Frankish, A., Diekhans, M., Ferreira, A.-M., Johnson, R., Jungreis, I., Loveland, J., Mudge, J.M., Sisu, C.,
00 Wright, J., Armstrong, J., et al. (2019). GENCODE reference annotation for the human and mouse genomes.
01 *Nucleic Acids Res.* 47, D766–D773.
- 02 Friedrich, M., Pohin, M., and Jackson, M. (2020). IL-1-driven stromal-neutrophil interaction in deep ulcers
03 identifies a pathotype of therapy non-responsive inflammatory bowel disease. In Review.
- 04 Gelman, A., and Su, Y.-S. (2020). arm: Data Analysis Using Regression and Multilevel/Hierarchical Models.
- 05 Gelman, A., Hill, J., and Yajima, M. (2012). Why We (Usually) Don't Have to Worry About Multiple
06 Comparisons. *J. Res. Educ. Eff.* 5, 189–211.
- 07 Germain, P. (2020). scDbIFinder: scDbIFinder. R package version 1.2.0.
- 08 GTEx Consortium (2015). Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis:
09 multitissue gene regulation in humans. *Science* 348, 648–660.
- 10 Habermann, A.C., Gutierrez, A.J., Bui, L.T., Yahn, S.L., Winters, N.I., Calvi, C.L., Peter, L., Chung, M.-I.,
11 Taylor, C.J., Jetter, C., et al. (2020). Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial
12 and mesenchymal lineages in pulmonary fibrosis. *Science Advances* 6, eaba1972.
- 13 Haghverdi, L., Lun, A.T.L., Morgan, M.D., and Marioni, J.C. (2018). Batch effects in single-cell RNA-
14 sequencing data are corrected by matching mutual nearest neighbors. *Nat. Biotechnol.* 36, 421–427.
- 15 He, H., Suryawanshi, H., Morozov, P., Gay-Mimbrera, J., Del Duca, E., Kim, H.J., Kameyama, N., Estrada, Y.,
16 Der, E., Krueger, J.G., et al. (2020). Single-cell transcriptome analysis of human skin identifies novel fibroblast
17 subpopulation and enrichment of immune subsets in atopic dermatitis. *J. Allergy Clin. Immunol.* 145, 1615–
18 1628.
- 19 Huang, B., Chen, Z., Geng, L., Wang, J., Liang, H., Cao, Y., Chen, H., Huang, W., Su, M., Wang, H., et al.
20 (2019). Mucosal Profiling of Pediatric-Onset Colitis and IBD Reveals Common Pathogenics and Therapeutic
21 Pathways. *Cell* 179, 1160-1176.e24.
- 22 Kang, J.B., Nathan, A., Millard, N., Rumker, L., Branch Moody, D., Korsunsky, I., and Raychaudhuri, S.
23 (2020). Efficient and precise single-cell reference atlas mapping with Symphony.
- 24 Kinchen, J., Chen, H.H., Parikh, K., Antanaviciute, A., Jagielowicz, M., Fawcner-Corbett, D., Ashley, N.,
25 Cubitt, L., Mellado-Gomez, E., Attar, M., et al. (2018). Structural Remodeling of the Human Colonic
26 Mesenchyme in Inflammatory Bowel Disease. *Cell* 175, 372-386.e17.
- 27 Koliarakis, V., Prados, A., Armaka, M., and Kollias, G. (2020). The mesenchymal context in inflammation,
28 immunity and cancer. *Nat. Immunol.* 21, 974–982.
- 29 Korsunsky, I., Millard, N., Fan, J., Slowikowski, K., Zhang, F., Wei, K., Baglaenko, Y., Brenner, M., Loh, P.-R.,
30 and Raychaudhuri, S. (2019). Fast, sensitive and accurate integration of single-cell data with Harmony. *Nat.*
31 *Methods* 16, 1289–1296.

- 32 Krenn, V., Morawietz, L., Burmester, G.-R., Kinne, R.W., Mueller-Ladner, U., Muller, B., and Haupl, T. (2006).
33 Synovitis score: discrimination between chronic low-grade and high-grade synovitis. *Histopathology* 49, 358–
34 364.
- 35 Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., and Mesirov, J.P. (2011).
36 Molecular signatures database (MSigDB) 3.0. *Bioinformatics* 27, 1739–1740.
- 37 Lotfollahi, M., Naghipourfar, M., Luecken, M.D., Khajavi, M., Büttner, M., Avsec, Z., Misharin, A.V., and Theis,
38 F.J. (2020). Query to reference single-cell integration with transfer learning.
- 39 Lun, A.T.L., and Marioni, J.C. (2017). Overcoming confounding plate effects in differential expression
40 analyses of single-cell RNA-seq data. *Biostatistics* 18, 451–464.
- 41 Machowicz, A., Hall, I., De Pablo, P., Rauz, S., Richards, A., Higham, J., Poveda-Gallego, A., Imamura, F.,
42 Bowman, S.J., Barone, F., et al. (2020). Mediterranean diet and risk of Sjögren’s syndrome.
- 43 Marchal-Bressenot, A., Salleron, J., Boulagnon-Rombi, C., Bastien, C., Cahn, V., Cadiot, G., Diebold, M.-D.,
44 Danese, S., Reinisch, W., Schreiber, S., et al. (2017). Development and validation of the Nancy histological
45 index for UC. *Gut* 66, 43–49.
- 46 Martin, J.C., Chang, C., Boschetti, G., Ungaro, R., Giri, M., Grout, J.A., Gettler, K., Chuang, L.-S., Nayar, S.,
47 Greenstein, A.J., et al. (2019). Single-Cell Analysis of Crohn’s Disease Lesions Identifies a Pathogenic
48 Cellular Module Associated with Resistance to Anti-TNF Therapy. *Cell* 178, 1493-1508.e20.
- 49 Melsted, P., Ntranos, V., and Pachter, L. (2019). The barcode, UMI, set format and BUSTools. *Bioinformatics*
50 35, 4472–4473.
- 51 Melville, J. (2020). uwot: The Uniform Manifold Approximation and Projection (UMAP) Method for
52 Dimensionality Reduction.
- 53 Mizoguchi, F., Slowikowski, K., Wei, K., Marshall, J.L., Rao, D.A., Chang, S.K., Nguyen, H.N., Noss, E.H.,
54 Turner, J.D., Earp, B.E., et al. (2018). Functionally distinct disease-associated fibroblast subsets in
55 rheumatoid arthritis. *Nat. Commun.* 9, 789.
- 56 Monach, P., Hattori, K., Huang, H., Hyatt, E., Morse, J., Nguyen, L., Ortiz-Lopez, A., Wu, H.-J., Mathis, D.,
57 and Benoist, C. (2007). The K/BxN mouse model of inflammatory arthritis: theory and practice. *Methods Mol.*
58 *Med.* 136, 269–282.
- 59 Nayar, S., Campos, J., Smith, C.G., Iannizzotto, V., Gardner, D.H., Mourcin, F., Roulois, D., Turner, J.,
60 Sylvestre, M., Asam, S., et al. (2019). Immunofibroblasts are pivotal drivers of tertiary lymphoid structure
61 formation and local pathology. *Proc. Natl. Acad. Sci. U. S. A.* 116, 13490–13497.
- 62 Ng, B., Dong, J., Viswanathan, S., Widjaja, A.A., Paleja, B.S., Adami, E., Ko, N.S.J., Wang, M., Lim, S., Tan,
63 J., et al. (2020). Fibroblast-specific IL11 signaling drives chronic inflammation in murine fibrotic lung disease.
64 *FASEB J.* 34, 11802–11815.
- 65 Nguyen, H.N., Noss, E.H., Mizoguchi, F., Huppertz, C., Wei, K.S., Watts, G.F.M., and Brenner, M.B. (2017).
66 Autocrine Loop Involving IL-6 Family Member LIF, LIF Receptor, and STAT4 Drives Sustained Fibroblast
67 Production of Inflammatory Mediators. *Immunity* 46, 220–232.
- 68 Nieto, P., Elosua-Bayes, M., Trincado, J.L., Marchese, D., Massoni-Badosa, R., Salvany, M., Henriques, A.,
69 Mereu, E., Moutinho, C., Ruiz, S., et al. (2020). A Single-Cell Tumor Immune Atlas for Precision Oncology.
- 70 Rafii, S., Butler, J.M., and Ding, B.-S. (2016). Angiocrine functions of organ-specific endothelial cells. *Nature*
71 529, 316–325.

- 72 Ramilowski, J.A., Goldberg, T., Harshbarger, J., Kloppmann, E., Lizio, M., Satagopam, V.P., Itoh, M., Kawaji,
73 H., Carninci, P., Rost, B., et al. (2015). A draft network of ligand-receptor-mediated multicellular signalling in
74 human. *Nat. Commun.* 6, 7866.
- 75 Rudno-Rudzińska, J., Kielan, W., Frejlich, E., Kotulski, K., Hap, W., Kurnol, K., Dzierżek, P., Zawadzki, M.,
76 and Hałoń, A. (2017). A review on Eph/ephrin, angiogenesis and lymphangiogenesis in gastric, colorectal and
77 pancreatic cancers. *Chin. J. Cancer Res.* 29, 303–312.
- 78 Schneider, V.A., Graves-Lindsay, T., Howe, K., Bouk, N., Chen, H.-C., Kitts, P.A., Murphy, T.D., Pruitt, K.D.,
79 Thibaud-Nissen, F., Albracht, D., et al. (2017). Evaluation of GRCh38 and de novo haploid genome
80 assemblies demonstrates the enduring quality of the reference assembly. *Genome Res.* 27, 849–864.
- 81 Sergushichev, A. (2016). An algorithm for fast preranked gene set enrichment analysis using cumulative
82 statistic calculation. *BioRxiv*.
- 83 Slowikowski, K., Nguyen, H.N., Noss, E.H., Simmons, D.P., Mizoguchi, F., Watts, G.F.M., Gurish, M.F.,
84 Brenner, M.B., and Raychaudhuri, S. (2019). CUX1 and IκBζ mediate the synergistic inflammatory response
85 to TNF and IL-17A in stromal fibroblasts.
- 86 Smillie, C.S., Biton, M., Ordovas-Montanes, J., Sullivan, K.M., Burgin, G., Graham, D.B., Herbst, R.H., Rogel,
87 N., Slyper, M., Waldman, J., et al. (2019). Intra- and Inter-cellular Rewiring of the Human Colon during
88 Ulcerative Colitis. *Cell* 178, 714-730.e22.
- 89 Szabo, P.A., Levitin, H.M., Miron, M., Snyder, M.E., Senda, T., Yuan, J., Cheng, Y.L., Bush, E.C., Dogra, P.,
90 Thapa, P., et al. (2019). Single-cell transcriptomics of human T cells reveals tissue and activation signatures
91 in health and disease. *Nat. Commun.* 10, 4706.
- 92 Tran, H.T.N., Ang, K.S., Chevrier, M., Zhang, X., Lee, N.Y.S., Goh, M., and Chen, J. (2020). A benchmark of
93 batch-effect correction methods for single-cell RNA sequencing data. *Genome Biol.* 21, 12.
- 94 Tsukui, T., Sun, K.-H., Wetter, J.B., Wilson-Kanamori, J.R., Hazelwood, L.A., Henderson, N.C., Adams, T.S.,
95 Schupp, J.C., Poli, S.D., Rosas, I.O., et al. (2020). Collagen-producing lung cell atlas identifies multiple
96 subsets with distinct localization and relevance to fibrosis. *Nat. Commun.* 11, 1920.
- 97 Veroniki, A.A., Jackson, D., Viechtbauer, W., Bender, R., Bowden, J., Knapp, G., Kuss, O., Higgins, J.P.T.,
98 Langan, D., and Salanti, G. (2016). Methods to estimate the between-study variance and its uncertainty in
99 meta-analysis. *Res Synth Methods* 7, 55–79.
- 00 Weckbach, L.T., Groesser, L., Borgolte, J., Pagel, J.-I., Pogoda, F., Schymeinsky, J., Müller-Höcker, J.,
01 Shakibaei, M., Muramatsu, T., Deindl, E., et al. (2012). Midkine acts as proangiogenic cytokine in hypoxia-
02 induced angiogenesis. *Am. J. Physiol. Heart Circ. Physiol.* 303, H429-38.
- 03 Wei, K., Korsunsky, I., Marshall, J.L., Gao, A., Watts, G.F.M., Major, T., Croft, A.P., Watts, J., Blazar, P.E.,
04 Lange, J.K., et al. (2020). Notch signalling drives synovial fibroblast identity and arthritis pathology. *Nature*
05 582, 259–264.
- 06 West, N.R. (2019). Coordination of Immune-Stroma Crosstalk by IL-6 Family Cytokines. *Front. Immunol.* 10,
07 1093.
- 08 West, N.R., Hegazy, A.N., Owens, B.M.J., Bullers, S.J., Linggi, B., Buonocore, S., Coccia, M., Görtz, D., This,
09 S., Stockenhuber, K., et al. (2017). Oncostatin M drives intestinal inflammation and predicts response to tumor
10 necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. *Nat. Med.* 23, 579–589.
- 11 Zhang, F., Wei, K., Slowikowski, K., Fonseka, C.Y., Rao, D.A., Kelly, S., Goodman, S.M., Tabechian, D.,
12 Hughes, L.B., Salomon-Escoto, K., et al. (2019). Defining inflammatory cell states in rheumatoid arthritis joint
13 synovial tissues by integrating single-cell transcriptomics and mass cytometry. *Nat. Immunol.*

- 14 Zhang, F., Mears, J.R., Shakib, L., Beynor, J.I., Shanaj, S., Korsunsky, I., Nathan, A., Donlin, L.T., and
15 Raychaudhuri, S. (2020). IFN- γ and TNF- α drive a CXCL10 + CCL2 + macrophage phenotype expanded in
16 severe COVID-19 and other diseases with tissue inflammation. BioRxiv.
- 17 Zheng, G.X.Y., Terry, J.M., Belgrader, P., Ryvkin, P., Bent, Z.W., Wilson, R., Ziraldo, S.B., Wheeler, T.D.,
18 McDermott, G.P., Zhu, J., et al. (2017). Massively parallel digital transcriptional profiling of single cells. Nat.
19 Commun. 8, 14049.